1
|
Major G, Ahn M, Cho WW, Santos M, Wise J, Phillips E, Wise SG, Jang J, Rnjak-Kovacina J, Woodfield T, Lim KS. Programming temporal stiffness cues within extracellular matrix hydrogels for modelling cancer niches. Mater Today Bio 2024; 25:101004. [PMID: 38420142 PMCID: PMC10900776 DOI: 10.1016/j.mtbio.2024.101004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2023] [Revised: 02/13/2024] [Accepted: 02/15/2024] [Indexed: 03/02/2024] Open
Abstract
Extracellular matrix (ECM) stiffening is a common occurrence during the progression of many diseases, such as breast cancer. To accurately mimic the pathophysiological context of disease within 3D in vitro models, there is high demand for smart biomaterials which replicate the dynamic and temporal mechanical cues of diseased states. This study describes a preclinical disease model, using breast cancer as an example, which replicates the dynamic plasticity of the tumour microenvironment by incorporating temporal (3-week progression) biomechanical cues within a tissue-specific hydrogel microenvironment. The composite hydrogel formulation, integrating adipose-derived decellularised ECM (AdECM) and silk fibroin, was initially crosslinked using a visible light-mediated system, and then progressively stiffened through spontaneous secondary structure interactions inherent between the polymer chains (∼10-15 kPa increase, with a final stiffness of 25 kPa). When encapsulated and cultured in vitro, MCF-7 breast cancer cells initially formed numerous, large spheroids (>1000 μm2 in area), however, with progressive temporal stiffening, cells demonstrated growth arrest and underwent phenotypic changes resulting in intratumoral heterogeneity. Unlike widely-investigated static mechanical models, this stiffening hydrogel allowed for progressive phenotypic changes to be observed, and fostered the development of mature organoid-like spheroids, which mimicked both the organisation and acinar-structures of mature breast epithelium. The spheroids contained a central population of cells which expressed aggressive cellular programs, evidenced by increased fibronectin expression and reduction of E-cadherin. The phenotypic heterogeneity observed using this model is more reflective of physiological tumours, demonstrating the importance of establishing temporal cues within preclinical models in future work. Overall, the developed model demonstrated a novel strategy to uncouple ECM biomechanical properties from the cellular complexities of the disease microenvironment and offers the potential for wide applicability in other 3D in vitro disease models through addition of tissue-specific dECM materials.
Collapse
Affiliation(s)
- Gretel Major
- Department of Orthopaedic Surgery and Musculoskeletal Medicine, Centre for Bioengineering & Nanomedicine, University of Otago, Christchurch, New Zealand
| | - Minjun Ahn
- Pohang University of Science and Technology (POSTECH), Pohang, South Korea
| | - Won-Woo Cho
- Pohang University of Science and Technology (POSTECH), Pohang, South Korea
| | - Miguel Santos
- Applied Materials Group, School of Medical Sciences, University of Sydney, Sydney, Australia
| | - Jessika Wise
- Mackenzie Cancer Research Group, Department of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand
| | - Elisabeth Phillips
- Mackenzie Cancer Research Group, Department of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand
| | - Steven G Wise
- Applied Materials Group, School of Medical Sciences, University of Sydney, Sydney, Australia
| | - Jinah Jang
- Pohang University of Science and Technology (POSTECH), Pohang, South Korea
| | - Jelena Rnjak-Kovacina
- Graduate School of Biomedical Engineering, University of New South Wales, Sydney, Australia
- Tyree Institute of Health Engineering, University of New South Wales, Sydney, NSW, 2052, Australia
| | - Tim Woodfield
- Department of Orthopaedic Surgery and Musculoskeletal Medicine, Centre for Bioengineering & Nanomedicine, University of Otago, Christchurch, New Zealand
| | - Khoon S Lim
- Department of Orthopaedic Surgery and Musculoskeletal Medicine, Centre for Bioengineering & Nanomedicine, University of Otago, Christchurch, New Zealand
- Light-Activated Materials Group, School of Medical Sciences, University of Sydney, Australia
| |
Collapse
|
2
|
Santos M, Michael PL, Mitchell TC, Lam YT, Robinson TM, Moore MJ, Tan RP, Rnjak-Kovacina J, Lim KS, Wise SG. On-Demand Bioactivation of Inert Materials With Plasma-Polymerized Nanoparticles. Adv Mater 2024:e2311313. [PMID: 38483292 DOI: 10.1002/adma.202311313] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/27/2023] [Revised: 02/05/2024] [Indexed: 03/22/2024]
Abstract
Conventional gas plasma treatments are crucial for functionalizing materials in biomedical applications, but have limitations hindering their broader use. These methods require exposure to reactive media under vacuum conditions, rendering them unsuitable for substrates that demand aqueous environments, such as proteins and hydrogels. In addition, complex geometries are difficult to treat, necessitating extensive customization for each material and shape. To address these constraints, an innovative approach employing plasma polymer nanoparticles (PPN) as a versatile functionalization tool is proposed. PPN share similarities with traditional plasma polymer coatings (PPC) but offer unique advantages: compatibility with aqueous systems, the ability to modify complex geometries, and availability as off-the-shelf products. Robust immobilization of PPN on various substrates, including synthetic polymers, proteins, and complex hydrogel structures is demonstrated in this study. This results in substantial improvements in surface hydrophilicity. Materials functionalization with arginylglycylaspartic acid (RGD)-loaded PPN significantly enhances cell attachment, spreading, and substrate coverage on inert scaffolds compared to passive RGD coatings. Improved adhesion to complex geometries and subsequent differentiation following growth factor exposure is also demonstrated. This research introduces a novel substrate functionalization approach that mimics the outcomes of plasma coating technology but vastly expands its applicability, promising advancements in biomedical materials and devices.
Collapse
Affiliation(s)
- Miguel Santos
- School of Medical Sciences, University of Sydney, Sydney, New South Wales, 2006, Australia
| | - Praveesuda L Michael
- School of Medical Sciences, University of Sydney, Sydney, New South Wales, 2006, Australia
| | - Timothy C Mitchell
- School of Medical Sciences, University of Sydney, Sydney, New South Wales, 2006, Australia
| | - Yuen Ting Lam
- School of Medical Sciences, University of Sydney, Sydney, New South Wales, 2006, Australia
| | - Thomas M Robinson
- School of Medical Sciences, University of Sydney, Sydney, New South Wales, 2006, Australia
| | - Mathew J Moore
- School of Medical Sciences, University of Sydney, Sydney, New South Wales, 2006, Australia
| | - Richard P Tan
- School of Medical Sciences, University of Sydney, Sydney, New South Wales, 2006, Australia
| | - Jelena Rnjak-Kovacina
- Graduate School of Biomedical Engineering, University of New South Wales, Sydney, New South Wales, 2006, Australia
| | - Khoon S Lim
- School of Medical Sciences, University of Sydney, Sydney, New South Wales, 2006, Australia
| | - Steven G Wise
- School of Medical Sciences, University of Sydney, Sydney, New South Wales, 2006, Australia
| |
Collapse
|
3
|
Jiang S, Wise SG, Kovacic JC, Rnjak-Kovacina J, Lord MS. Biomaterials containing extracellular matrix molecules as biomimetic next-generation vascular grafts. Trends Biotechnol 2024; 42:369-381. [PMID: 37852854 DOI: 10.1016/j.tibtech.2023.09.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2023] [Revised: 09/18/2023] [Accepted: 09/19/2023] [Indexed: 10/20/2023]
Abstract
The performance of synthetic biomaterial vascular grafts for the bypass of stenotic and dysfunctional blood vessels remains an intractable challenge in small-diameter applications. The functionalization of biomaterials with extracellular matrix (ECM) molecules is a promising approach because these molecules can regulate multiple biological processes in vascular tissues. In this review, we critically examine emerging approaches to ECM-containing vascular graft biomaterials and explore opportunities for future research and development toward clinical use.
Collapse
Affiliation(s)
- Shouyuan Jiang
- Graduate School of Biomedical Engineering, University of New South Wales, Sydney, NSW 2052, Australia
| | - Steven G Wise
- School of Medical Sciences, Faculty of Health and Medicine, University of Sydney, Sydney, NSW 2006, Australia; Charles Perkins Centre, University of Sydney, Sydney, NSW 2006, Australia; The University of Sydney Nano Institute, University of Sydney, Sydney, NSW 2006, Australia
| | - Jason C Kovacic
- Victor Chang Cardiac Research Institute, Darlinghurst, NSW 2010, Australia; St Vincent's Clinical School, University of New South Wales, Darlinghurst, NSW 2010, Australia; Cardiovascular Research Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Jelena Rnjak-Kovacina
- Graduate School of Biomedical Engineering, University of New South Wales, Sydney, NSW 2052, Australia
| | - Megan S Lord
- Graduate School of Biomedical Engineering, University of New South Wales, Sydney, NSW 2052, Australia.
| |
Collapse
|
4
|
Major GS, Doan VK, Longoni A, Bilek MMM, Wise SG, Rnjak-Kovacina J, Yeo GC, Lim KS. Mapping the microcarrier design pathway to modernise clinical mesenchymal stromal cell expansion. Trends Biotechnol 2024:S0167-7799(24)00001-5. [PMID: 38320911 DOI: 10.1016/j.tibtech.2024.01.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2023] [Revised: 01/08/2024] [Accepted: 01/08/2024] [Indexed: 02/08/2024]
Abstract
Microcarrier expansion systems show exciting potential to revolutionise mesenchymal stromal cell (MSC)-based clinical therapies by providing an opportunity for economical large-scale expansion of donor- and patient-derived cells. The poor reproducibility and efficiency of cell expansion on commercial polystyrene microcarriers have driven the development of novel microcarriers with tuneable physical, mechanical, and cell-instructive properties. These new microcarriers show innovation toward improving cell expansion outcomes, although their limited biological characterisation and compatibility with dynamic culture systems suggest the need to realign the microcarrier design pathway. Clear headway has been made toward developing infrastructure necessary for scaling up these technologies; however, key challenges remain in characterising the wholistic effects of microcarrier properties on the biological fate and function of expanded MSCs.
Collapse
Affiliation(s)
- Gretel S Major
- School of Medical Sciences, University of Sydney, Sydney, Australia
| | - Vinh K Doan
- School of Medical Sciences, University of Sydney, Sydney, Australia
| | - Alessia Longoni
- Department of Orthopedics, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Marcela M M Bilek
- School of Biomedical Engineering, University of Sydney, Sydney, Australia; School of Physics, University of Sydney, Sydney, Australia; Charles Perkins Centre, University of Sydney, Sydney, Australia; Sydney Nano Institute, University of Sydney, Sydney, Australia
| | - Steven G Wise
- School of Medical Sciences, University of Sydney, Sydney, Australia; Charles Perkins Centre, University of Sydney, Sydney, Australia
| | - Jelena Rnjak-Kovacina
- Graduate School of Biomedical Engineering, University of New South Wales, Sydney, Australia; Tyree Institute of Health Engineering, University of New South Wales, Sydney, Australia
| | - Giselle C Yeo
- Charles Perkins Centre, University of Sydney, Sydney, Australia; School of Life and Environmental Sciences, University of Sydney, Sydney, Australia.
| | - Khoon S Lim
- School of Medical Sciences, University of Sydney, Sydney, Australia; Charles Perkins Centre, University of Sydney, Sydney, Australia; Sydney Nano Institute, University of Sydney, Sydney, Australia.
| |
Collapse
|
5
|
Cao J, Liu JH, Wise SG, Fan J, Bao S, Zheng GS. The role of IL-36 and 37 in hepatocellular carcinoma. Front Immunol 2024; 15:1281121. [PMID: 38312834 PMCID: PMC10834741 DOI: 10.3389/fimmu.2024.1281121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2023] [Accepted: 01/05/2024] [Indexed: 02/06/2024] Open
Abstract
Hepatocellular carcinoma (HCC) has garnered considerable attention due to its morbidity and mortality. Although the precise mechanisms underlying HCC tumorigenesis remain to be elucidated, evidence suggests that host immunity plays a pivotal role in its development. IL-36 and IL-37 are important immunoregulatory cytokines classified as pro-inflammatory and anti-inflammatory respectively. In the context of HCC, the downregulation of intrahepatic IL-36 is inversely correlated with cirrhosis, but positively correlated with 5-year survival rates, suggesting that IL-36 offers protection during HCC development. However, IL-36 may lose its hepatoprotective effects as the disease progresses to HCC in the context of dysregulated immunity in cirrhotic patients. Substantially increased circulating IL-36 in HCC patients is likely a systemic response to HCC stimulation, but is insufficient to suppress progression towards HCC. Intrahepatic IL-37 is suppressed in HCC patients, consistent with the inverse correlation between intrahepatic IL-37 and the level of AFP in HCC patients, suggesting IL-37 exerts hepatoprotection. There is no significant difference in IL-37 among differentiations of HCC or with respect to clinical BCLC stages or cirrhosis status in HCC patients. However, IL-37 protection is demonstrated in an IL-37 transfected HCC animal model, showing significantly reduced tumour size. IL-36/37 may inhibit HCC by enhancing M1 tumour-associated macrophages while not affecting M2 macrophages. The interplay between IL-36 (pro-inflammatory) and IL-37 (anti-inflammatory) is emerging as a crucial factor in host protection against the development of HCC. Further research is needed to investigate the complex mechanisms involved and the therapeutic potential of targeting these cytokines in HCC management.
Collapse
Affiliation(s)
- Juan Cao
- Basic Medical College, Gansu University of Chinese Medicine, Lanzhou, China
- Department of Public Health, Affiliated Hospital of Gansu University of Chinese Medicine, Lanzhou, China
| | - Jun-Hong Liu
- Department of Public Health, Affiliated Hospital of Gansu University of Chinese Medicine, Lanzhou, China
- Gansu Provincial Integrated Traditional Chinese and Western Medicine Digestive Disease Clinical Research Centre, Lanzhou, China
| | - Steven G. Wise
- School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia
| | - Jingchun Fan
- School of Public Health, Gansu University of Chinese Medicine, Lanzhou, China
| | - Shisan Bao
- School of Public Health, Gansu University of Chinese Medicine, Lanzhou, China
| | - Gui-Sen Zheng
- School of Public Health, Gansu University of Chinese Medicine, Lanzhou, China
| |
Collapse
|
6
|
Chan AHP, Moore MJ, Grant AJ, Lam YTM, Darnell MV, Michael PL, Wise SG, Tan RP. Selective Immunosuppression Targeting the NLRP3 Inflammasome Mitigates the Foreign Body Response to Implanted Biomaterials While Preserving Angiogenesis. Adv Healthc Mater 2023; 12:e2301571. [PMID: 37846971 DOI: 10.1002/adhm.202301571] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2023] [Revised: 10/04/2023] [Indexed: 10/18/2023]
Abstract
Medical devices are a mainstay of the healthcare industry, providing clinicians with innovative tools to diagnose, monitor, and treat a range of medical conditions. For implantable devices, it is widely regarded that chronic inflammation during the foreign body response (FBR) is detrimental to device performance, but also required for tissue regeneration and host integration. Current strategies to mitigate the FBR rely on broad acting anti-inflammatory drugs, most commonly, dexamethasone (DEX), which can inhibit angiogenesis and compromise long-term device function. This study challenges prevailing assumptions by suggesting that FBR inflammation is multifaceted, and selectively targeting its individual pathways can stop implant fibrosis while preserving beneficial repair pathways linked to improved device performance. MCC950, an anti-inflammatory drug that selectively inhibits the NLRP3 inflammasome, targets pathological inflammation without compromising global immune function. The effects of MCC950 and DEX on the FBR are compared using implanted polycaprolactone (PCL) scaffolds. The results demonstrate that both DEX and MCC950 halt immune cell recruitment and cytokine release, leading to reduced FBR. However, MCC950 achieves this while supporting capillary growth and enhancing tissue angiogenesis. These findings support selective immunosuppression approaches as a potential future direction for treating the FBR and enhancing the longevity and safety of implantable devices.
Collapse
Affiliation(s)
- Alex H P Chan
- School of Medical Sciences, Faculty of Health and Medicine, University of Sydney, Sydney, NSW, 2006, Australia
- Charles Perkins Centre, University of Sydney, Sydney, NSW, 2006, Australia
| | - Matthew J Moore
- School of Medical Sciences, Faculty of Health and Medicine, University of Sydney, Sydney, NSW, 2006, Australia
- Charles Perkins Centre, University of Sydney, Sydney, NSW, 2006, Australia
| | - Angus J Grant
- School of Medical Sciences, Faculty of Health and Medicine, University of Sydney, Sydney, NSW, 2006, Australia
- Charles Perkins Centre, University of Sydney, Sydney, NSW, 2006, Australia
| | - Yuen Ting Monica Lam
- School of Medical Sciences, Faculty of Health and Medicine, University of Sydney, Sydney, NSW, 2006, Australia
- Charles Perkins Centre, University of Sydney, Sydney, NSW, 2006, Australia
| | - Matthew V Darnell
- School of Medical Sciences, Faculty of Health and Medicine, University of Sydney, Sydney, NSW, 2006, Australia
- Charles Perkins Centre, University of Sydney, Sydney, NSW, 2006, Australia
| | - Praveesuda L Michael
- School of Medical Sciences, Faculty of Health and Medicine, University of Sydney, Sydney, NSW, 2006, Australia
- Charles Perkins Centre, University of Sydney, Sydney, NSW, 2006, Australia
| | - Steven G Wise
- School of Medical Sciences, Faculty of Health and Medicine, University of Sydney, Sydney, NSW, 2006, Australia
- Charles Perkins Centre, University of Sydney, Sydney, NSW, 2006, Australia
| | - Richard P Tan
- School of Medical Sciences, Faculty of Health and Medicine, University of Sydney, Sydney, NSW, 2006, Australia
- Charles Perkins Centre, University of Sydney, Sydney, NSW, 2006, Australia
| |
Collapse
|
7
|
Xin H, Tomaskovic-Crook E, Al Maruf DSA, Cheng K, Wykes J, Manzie TGH, Wise SG, Crook JM, Clark JR. From Free Tissue Transfer to Hydrogels: A Brief Review of the Application of the Periosteum in Bone Regeneration. Gels 2023; 9:768. [PMID: 37754449 PMCID: PMC10530949 DOI: 10.3390/gels9090768] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2023] [Revised: 09/15/2023] [Accepted: 09/18/2023] [Indexed: 09/28/2023] Open
Abstract
The periosteum is a thin layer of connective tissue covering bone. It is an essential component for bone development and fracture healing. There has been considerable research exploring the application of the periosteum in bone regeneration since the 19th century. An increasing number of studies are focusing on periosteal progenitor cells found within the periosteum and the use of hydrogels as scaffold materials for periosteum engineering and guided bone development. Here, we provide an overview of the research investigating the use of the periosteum for bone repair, with consideration given to the anatomy and function of the periosteum, the importance of the cambium layer, the culture of periosteal progenitor cells, periosteum-induced ossification, periosteal perfusion, periosteum engineering, scaffold vascularization, and hydrogel-based synthetic periostea.
Collapse
Affiliation(s)
- Hai Xin
- Integrated Prosthetics and Reconstruction, Department of Head and Neck Surgery, Chris O’Brien Lifehouse, Camperdown, NSW 2050, Australia; (D.S.A.A.M.); (K.C.); (J.W.); (T.G.H.M.); (J.R.C.)
- Central Clinical School, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2050, Australia
| | - Eva Tomaskovic-Crook
- Arto Hardy Family Biomedical Innovation Hub, Chris O’Brien Lifehouse, Camperdown, NSW 2050, Australia; (E.T.-C.); (J.M.C.)
- School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2006, Australia;
- Intelligent Polymer Research Institute, AIIM Facility, Innovation Campus, University of Wollongong, North Wollongong, NSW 2500, Australia
| | - D S Abdullah Al Maruf
- Integrated Prosthetics and Reconstruction, Department of Head and Neck Surgery, Chris O’Brien Lifehouse, Camperdown, NSW 2050, Australia; (D.S.A.A.M.); (K.C.); (J.W.); (T.G.H.M.); (J.R.C.)
- Central Clinical School, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2050, Australia
| | - Kai Cheng
- Integrated Prosthetics and Reconstruction, Department of Head and Neck Surgery, Chris O’Brien Lifehouse, Camperdown, NSW 2050, Australia; (D.S.A.A.M.); (K.C.); (J.W.); (T.G.H.M.); (J.R.C.)
- Royal Prince Alfred Institute of Academic Surgery, Royal Prince Alfred Hospital, Sydney Local Health District, Camperdown, NSW 2050, Australia
| | - James Wykes
- Integrated Prosthetics and Reconstruction, Department of Head and Neck Surgery, Chris O’Brien Lifehouse, Camperdown, NSW 2050, Australia; (D.S.A.A.M.); (K.C.); (J.W.); (T.G.H.M.); (J.R.C.)
- Central Clinical School, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2050, Australia
| | - Timothy G. H. Manzie
- Integrated Prosthetics and Reconstruction, Department of Head and Neck Surgery, Chris O’Brien Lifehouse, Camperdown, NSW 2050, Australia; (D.S.A.A.M.); (K.C.); (J.W.); (T.G.H.M.); (J.R.C.)
| | - Steven G. Wise
- School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2006, Australia;
| | - Jeremy M. Crook
- Arto Hardy Family Biomedical Innovation Hub, Chris O’Brien Lifehouse, Camperdown, NSW 2050, Australia; (E.T.-C.); (J.M.C.)
- School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2006, Australia;
- Intelligent Polymer Research Institute, AIIM Facility, Innovation Campus, University of Wollongong, North Wollongong, NSW 2500, Australia
| | - Jonathan R. Clark
- Integrated Prosthetics and Reconstruction, Department of Head and Neck Surgery, Chris O’Brien Lifehouse, Camperdown, NSW 2050, Australia; (D.S.A.A.M.); (K.C.); (J.W.); (T.G.H.M.); (J.R.C.)
- Central Clinical School, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2050, Australia
- Royal Prince Alfred Institute of Academic Surgery, Royal Prince Alfred Hospital, Sydney Local Health District, Camperdown, NSW 2050, Australia
| |
Collapse
|
8
|
Lam YT, Lee BSL, Hung J, Michael P, Santos M, Tan RP, Liu R, Wise SG. Delivery of Therapeutic miRNA via Plasma-Polymerised Nanoparticles Rescues Diabetes-Impaired Endothelial Function. Nanomaterials (Basel) 2023; 13:2360. [PMID: 37630945 PMCID: PMC10459051 DOI: 10.3390/nano13162360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/28/2023] [Revised: 08/16/2023] [Accepted: 08/16/2023] [Indexed: 08/27/2023]
Abstract
MicroRNAs (miRNAs) are increasingly recognised as key regulators of the development and progression of many diseases due to their ability to modulate gene expression post-translationally. While this makes them an attractive therapeutic target, clinical application of miRNA therapy remains at an early stage and in part is limited by the lack of effective delivery modalities. Here, we determined the feasibility of delivering miRNA using a new class of plasma-polymerised nanoparticles (PPNs), which we have recently isolated and characterised. We showed that PPN-miRNAs have no significant effect on endothelial cell viability in vitro in either normal media or in the presence of high-glucose conditions. Delivery of a miRNA inhibitor targeting miR-503 suppressed glucose-induced miR-503 upregulation and restored the downstream mRNA expression of CCNE1 and CDC25a in endothelial cells. Subsequently, PPN delivery of miR-503 inhibitors enhanced endothelial angiogenesis, including tubulogenesis and migration, in culture conditions that mimic diabetic ischemia. An intramuscular injection of a PPN-miR-503 inhibitor promoted blood-perfusion recovery in the hindlimb of diabetic mice following surgically induced ischemia, linked with an increase in new blood vessel formation. Together, this study demonstrates the effective use of PPN to deliver therapeutic miRNAs in the context of diabetes.
Collapse
Affiliation(s)
- Yuen Ting Lam
- Chronic Diseases Theme, School of Medical Science, University of Sydney, Sydney 2006, Australia
- Charles Perkins Centre, University of Sydney, Sydney 2006, Australia
| | - Bob S. L. Lee
- Victor Chang Cardiac Research Institute, Darlinghurst 2010, Australia
- St. Vincent’s Clinical School, University of New South Wales, Darlinghurst 2010, Australia
- School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, Sydney 2050, Australia
| | - Juichien Hung
- Chronic Diseases Theme, School of Medical Science, University of Sydney, Sydney 2006, Australia
- Charles Perkins Centre, University of Sydney, Sydney 2006, Australia
| | - Praveesuda Michael
- Chronic Diseases Theme, School of Medical Science, University of Sydney, Sydney 2006, Australia
- Charles Perkins Centre, University of Sydney, Sydney 2006, Australia
| | - Miguel Santos
- Chronic Diseases Theme, School of Medical Science, University of Sydney, Sydney 2006, Australia
- Charles Perkins Centre, University of Sydney, Sydney 2006, Australia
| | - Richard P. Tan
- Chronic Diseases Theme, School of Medical Science, University of Sydney, Sydney 2006, Australia
- Charles Perkins Centre, University of Sydney, Sydney 2006, Australia
| | - Renjing Liu
- Victor Chang Cardiac Research Institute, Darlinghurst 2010, Australia
- St. Vincent’s Clinical School, University of New South Wales, Darlinghurst 2010, Australia
- School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, Sydney 2050, Australia
| | - Steven G. Wise
- Chronic Diseases Theme, School of Medical Science, University of Sydney, Sydney 2006, Australia
- Charles Perkins Centre, University of Sydney, Sydney 2006, Australia
| |
Collapse
|
9
|
Tan RP, Hung JC, Chan AHP, Grant AJ, Moore MJ, Lam YT, Michael P, Wise SG. Highly reproducible rat arterial injury model of neointimal hyperplasia. PLoS One 2023; 18:e0290342. [PMID: 37590291 PMCID: PMC10434902 DOI: 10.1371/journal.pone.0290342] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2023] [Accepted: 08/03/2023] [Indexed: 08/19/2023] Open
Abstract
Models of arterial injury in rodents have been invaluable to our current understanding of vessel restenosis and play a continuing role in the development of endovascular interventions for cardiovascular disease. Mechanical distention of the vessel wall and denudation of the vessel endothelium are the two major modes of vessel injury observed in most clinical pathologies and are critical to the reproducible modelling of progressive neointimal hyperplasia. The current models which have dominated this research area are the mouse wire carotid or femoral injury and the rat carotid balloon injury. While these elicit simultaneous distension of the vessel wall and denudation of the luminal endothelium, each model carries limitations that need to be addressed using a complementary injury model. Wire injuries in mice are highly technical and procedurally challenging due to small vessel diameters, while rat balloon injuries require permanent blood vessel ligation and disruption of native blood flow. Complementary models of vascular injury with reproducibility, convenience, and increased physiological relevance to the pathophysiology of endovascular injury would allow for improved studies of neointimal hyperplasia in both basic and translational research. In this study, we developed a new surgical model that elicits vessel distention and endothelial denudation injury using sequential steps using microforceps and a standard needle catheter inserted via arteriotomy into a rat common carotid artery, without requiring permanent ligation of branching arteries. After 2 weeks post-injury this model elicits highly reproducible neointimal hyperplasia and rates of re-endothelialisation similar to current wire and balloon injury models. Furthermore, evaluation of the smooth muscle cell phenotype profile, inflammatory response and extracellular matrix within the developing neointima, showed that our model replicated the vessel remodelling outcomes critical to restenosis and those becoming increasingly focused upon in the development of new anti-restenosis therapies.
Collapse
Affiliation(s)
- Richard P. Tan
- Faculty of Health and Medicine, School of Medical Sciences, University of Sydney, Sydney, NSW, Australia
- Charles Perkins Centre, University of Sydney, Sydney, NSW, Australia
| | - Jui Chien Hung
- Faculty of Health and Medicine, School of Medical Sciences, University of Sydney, Sydney, NSW, Australia
- Charles Perkins Centre, University of Sydney, Sydney, NSW, Australia
| | - Alex H. P. Chan
- Faculty of Health and Medicine, School of Medical Sciences, University of Sydney, Sydney, NSW, Australia
- Charles Perkins Centre, University of Sydney, Sydney, NSW, Australia
| | - Angus J. Grant
- Faculty of Health and Medicine, School of Medical Sciences, University of Sydney, Sydney, NSW, Australia
- Charles Perkins Centre, University of Sydney, Sydney, NSW, Australia
| | - Matthew J. Moore
- Faculty of Health and Medicine, School of Medical Sciences, University of Sydney, Sydney, NSW, Australia
- Charles Perkins Centre, University of Sydney, Sydney, NSW, Australia
| | - Yuen Ting Lam
- Faculty of Health and Medicine, School of Medical Sciences, University of Sydney, Sydney, NSW, Australia
- Charles Perkins Centre, University of Sydney, Sydney, NSW, Australia
| | - Praveesuda Michael
- Faculty of Health and Medicine, School of Medical Sciences, University of Sydney, Sydney, NSW, Australia
- Charles Perkins Centre, University of Sydney, Sydney, NSW, Australia
| | - Steven G. Wise
- Faculty of Health and Medicine, School of Medical Sciences, University of Sydney, Sydney, NSW, Australia
- Charles Perkins Centre, University of Sydney, Sydney, NSW, Australia
| |
Collapse
|
10
|
Xin H, Romanazzo S, Tomaskovic-Crook E, Mitchell TC, Hung JC, Wise SG, Cheng K, Al Maruf DSA, Stokan MJ, Manzie TGH, Parthasarathi K, Cheung VKY, Gupta R, Ly M, Pulitano C, Wise IK, Crook JM, Clark JR. Ex Vivo Preservation of Ovine Periosteum Using a Perfusion Bioreactor System. Cells 2023; 12:1724. [PMID: 37443758 PMCID: PMC10340137 DOI: 10.3390/cells12131724] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2023] [Revised: 06/16/2023] [Accepted: 06/20/2023] [Indexed: 07/15/2023] Open
Abstract
Periosteum is a highly vascularized membrane lining the surface of bones. It plays essential roles in bone repair following injury and reconstruction following invasive surgeries. To broaden the use of periosteum, including for augmenting in vitro bone engineering and/or in vivo bone repair, we have developed an ex vivo perfusion bioreactor system to maintain the cellular viability and metabolism of surgically resected periosteal flaps. Each specimen was placed in a 3D printed bioreactor connected to a peristaltic pump designed for the optimal flow rates of tissue perfusate. Nutrients and oxygen were perfused via the periosteal arteries to mimic physiological conditions. Biochemical assays and histological staining indicate component cell viability after perfusion for almost 4 weeks. Our work provides the proof-of-concept of ex vivo periosteum perfusion for long-term tissue preservation, paving the way for innovative bone engineering approaches that use autotransplanted periosteum to enhance in vivo bone repair.
Collapse
Affiliation(s)
- Hai Xin
- Integrated Prosthetics and Reconstruction, Department of Head and Neck Surgery, Chris O’Brien Lifehouse, Camperdown, NSW 2050, Australia
- Central Clinical School, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2050, Australia
| | - Sara Romanazzo
- Arto Hardy Family Biomedical Innovation Hub, Chris O’Brien Lifehouse, Camperdown, NSW 2050, Australia
| | - Eva Tomaskovic-Crook
- Arto Hardy Family Biomedical Innovation Hub, Chris O’Brien Lifehouse, Camperdown, NSW 2050, Australia
- School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia
- Intelligent Polymer Research Institute, University of Wollongong, Innovation Campus, Squires Way, North Wollongong, NSW 2500, Australia
| | - Timothy C. Mitchell
- School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia
| | - Jui Chien Hung
- School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia
| | - Steven G. Wise
- School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia
| | - Kai Cheng
- Integrated Prosthetics and Reconstruction, Department of Head and Neck Surgery, Chris O’Brien Lifehouse, Camperdown, NSW 2050, Australia
- Royal Prince Alfred Institute of Academic Surgery, Royal Prince Alfred Hospital, Sydney Local Health District, Camperdown, NSW 2050, Australia
| | - D S Abdullah Al Maruf
- Integrated Prosthetics and Reconstruction, Department of Head and Neck Surgery, Chris O’Brien Lifehouse, Camperdown, NSW 2050, Australia
- Central Clinical School, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2050, Australia
| | - Murray J. Stokan
- Integrated Prosthetics and Reconstruction, Department of Head and Neck Surgery, Chris O’Brien Lifehouse, Camperdown, NSW 2050, Australia
| | - Timothy G. H. Manzie
- Integrated Prosthetics and Reconstruction, Department of Head and Neck Surgery, Chris O’Brien Lifehouse, Camperdown, NSW 2050, Australia
| | - Krishnan Parthasarathi
- Integrated Prosthetics and Reconstruction, Department of Head and Neck Surgery, Chris O’Brien Lifehouse, Camperdown, NSW 2050, Australia
| | - Veronica K. Y. Cheung
- Central Clinical School, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2050, Australia
- The Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, NSW 2050, Australia
| | - Ruta Gupta
- Central Clinical School, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2050, Australia
- The Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, NSW 2050, Australia
| | - Mark Ly
- Central Clinical School, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2050, Australia
- RPA Translational Center for Organ Assessment, Repair, and Optimization, Royal Prince Alfred Hospital, Camperdown, NSW 2050, Australia
| | - Carlo Pulitano
- Central Clinical School, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2050, Australia
- RPA Translational Center for Organ Assessment, Repair, and Optimization, Royal Prince Alfred Hospital, Camperdown, NSW 2050, Australia
| | - Innes K. Wise
- Laboratory Animal Services, Charles Perkins Center, The University of Sydney, Camperdown, NSW 2050, Australia
| | - Jeremy M. Crook
- Arto Hardy Family Biomedical Innovation Hub, Chris O’Brien Lifehouse, Camperdown, NSW 2050, Australia
- School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia
- Intelligent Polymer Research Institute, University of Wollongong, Innovation Campus, Squires Way, North Wollongong, NSW 2500, Australia
| | - Jonathan R. Clark
- Integrated Prosthetics and Reconstruction, Department of Head and Neck Surgery, Chris O’Brien Lifehouse, Camperdown, NSW 2050, Australia
- Central Clinical School, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2050, Australia
- Royal Prince Alfred Institute of Academic Surgery, Royal Prince Alfred Hospital, Sydney Local Health District, Camperdown, NSW 2050, Australia
| |
Collapse
|
11
|
Clayton ZE, Santos M, Shah H, Lu J, Chen S, Shi H, Kanagalingam S, Michael PL, Wise SG, Chong JJH. Plasma polymerized nanoparticles are a safe platform for direct delivery of growth factor therapy to the injured heart. Front Bioeng Biotechnol 2023; 11:1127996. [PMID: 37409168 PMCID: PMC10319252 DOI: 10.3389/fbioe.2023.1127996] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2022] [Accepted: 05/31/2023] [Indexed: 07/07/2023] Open
Abstract
Introduction: Heart failure due to myocardial infarction is a progressive and debilitating condition, affecting millions worldwide. Novel treatment strategies are desperately needed to minimise cardiomyocyte damage after myocardial infarction and to promote repair and regeneration of the injured heart muscle. Plasma polymerized nanoparticles (PPN) are a new class of nanocarriers which allow for a facile, one-step functionalization with molecular cargo. Methods: Here, we conjugated platelet-derived growth factor AB (PDGF-AB) to PPN, engineering a stable nano-formulation, as demonstrated by optimal hydrodynamic parameters, including hydrodynamic size distribution, polydisperse index (PDI) and zeta potential, and further demonstrated safety and bioactivity in vitro and in vivo. We delivered PPN-PDGF-AB to human cardiac cells and directly to the injured rodent heart. Results: We found no evidence of cytotoxicity after delivery of PPN or PPN-PDGFAB to cardiomyocytes in vitro, as determined through viability and mitochondrial membrane potential assays. We then measured contractile amplitude of human stem cell derived cardiomyocytes and found no detrimental effect of PPN on cardiomyocyte contractility. We also confirmed that PDGF-AB remains functional when bound to PPN, with PDGF receptor alpha positive human coronary artery vascular smooth muscle cells and cardiac fibroblasts demonstrating migratory and phenotypic responses to PPN-PDGF-AB in the same manner as to unbound PDGF-AB. In our rodent model of PPN-PDGF-AB treatment after myocardial infarction, we found a modest improvement in cardiac function in PPN-PDGF-AB treated hearts compared to those treated with PPN, although this was not accompanied by changes in infarct scar size, scar composition, or border zone vessel density. Discussion: These results demonstrate safety and feasibility of the PPN platform for delivery of therapeutics directly to the myocardium. Future work will optimize PPN-PDGF-AB formulations for systemic delivery, including effective dosage and timing to enhance efficacy and bioavailability, and ultimately improve the therapeutic benefits of PDGF-AB in the treatment of heart failure cause by myocardial infarction.
Collapse
Affiliation(s)
- Zoë E. Clayton
- Westmead Institute for Medical Research, Sydney, NSW, Australia
- Sydney Medical School, University of Sydney, Sydney, NSW, Australia
| | - Miguel Santos
- School of Medical Sciences, Faculty of Health and Medicine, The University of Sydney, Sydney, NSW, Australia
- Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia
| | - Haisam Shah
- Westmead Institute for Medical Research, Sydney, NSW, Australia
- Sydney Medical School, University of Sydney, Sydney, NSW, Australia
| | - Juntang Lu
- Cardiology Department, Westmead Hospital, Sydney, NSW, Australia
| | - Siqi Chen
- Westmead Institute for Medical Research, Sydney, NSW, Australia
| | - Han Shi
- Westmead Institute for Medical Research, Sydney, NSW, Australia
- Sydney Medical School, University of Sydney, Sydney, NSW, Australia
| | | | - Praveesuda L. Michael
- School of Medical Sciences, Faculty of Health and Medicine, The University of Sydney, Sydney, NSW, Australia
- Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia
| | - Steven G. Wise
- School of Medical Sciences, Faculty of Health and Medicine, The University of Sydney, Sydney, NSW, Australia
- Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia
| | - James J. H. Chong
- Westmead Institute for Medical Research, Sydney, NSW, Australia
- Sydney Medical School, University of Sydney, Sydney, NSW, Australia
- Cardiology Department, Westmead Hospital, Sydney, NSW, Australia
| |
Collapse
|
12
|
Moore MJ, Lam YT, Santos M, Tan RP, Yang N, Hung J, Li Z, Kilian KA, Rnjak-Kovacina J, Pitts JB, Menzel H, Wise SG. Evaluation of the Immune Response to Chitosan- graft-poly(caprolactone) Biopolymer Scaffolds. ACS Biomater Sci Eng 2023. [PMID: 37219536 DOI: 10.1021/acsbiomaterials.3c00553] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
Biomimetic scaffolds recreating key elements of the architecture and biological activity of the extracellular matrix have enormous potential for soft tissue engineering applications. Combining appropriate mechanical properties with select biological cues presents a challenge for bioengineering, as natural materials are most bioactive but can lack mechanical integrity, while synthetic polymers have strength but are often biologically inert. Blends of synthetic and natural materials, aiming to combine the benefits of each, have shown promise but inherently require a compromise, diluting down favorable properties in each polymer to accommodate the other. Here, we electrospun a material comprising chitosan, a natural polysaccharide, and polycaprolactone (PCL), one of the most widely studied synthetic polymers used in materials engineering. In contrast to a classical blend, here PCL was chemically grafted onto the chitosan backbone to create chitosan-graft-polycaprolactone (CS-g-PCL) and then combined further with unmodified PCL to generate scaffolds with discreet chitosan functionalization. These small amounts of chitosan led to significant changes in scaffold architecture and surface chemistry, reducing the fiber diameter, pore size, and hydrophobicity. Interestingly, all CS-g-PCL-containing blends were stronger than control PCL, though with reduced elongation. In in vitro assessments, increasing the CS-g-PCL content led to significant improvements in in vitro blood compatibility compared to PCL alone while increasing fibroblast attachment and proliferation. In a mouse subcutaneous implantation model, a higher CS-g-PCL content improved the immune response to the implants. Macrophages in tissues surrounding CS-g-PCL scaffolds decreased proportionately to the chitosan content by up to 65%, with a corresponding decrease in pro-inflammatory cytokines. These results suggest that CS-g-PCL is a promising hybrid material comprising natural and synthetic polymers with tailorable mechanical and biological properties, justifying further development and in vivo evaluation.
Collapse
Affiliation(s)
- Matthew J Moore
- School of Medical Sciences, Faculty of Health and Medicine, The University of Sydney, Camperdown, New South Wales 2006, Australia
- Charles Perkins Centre, The University of Sydney, Camperdown, New South Wales 2006, Australia
| | - Yuen Ting Lam
- School of Medical Sciences, Faculty of Health and Medicine, The University of Sydney, Camperdown, New South Wales 2006, Australia
- Charles Perkins Centre, The University of Sydney, Camperdown, New South Wales 2006, Australia
| | - Miguel Santos
- School of Medical Sciences, Faculty of Health and Medicine, The University of Sydney, Camperdown, New South Wales 2006, Australia
- Charles Perkins Centre, The University of Sydney, Camperdown, New South Wales 2006, Australia
| | - Richard P Tan
- School of Medical Sciences, Faculty of Health and Medicine, The University of Sydney, Camperdown, New South Wales 2006, Australia
- Charles Perkins Centre, The University of Sydney, Camperdown, New South Wales 2006, Australia
| | - Nianji Yang
- School of Medical Sciences, Faculty of Health and Medicine, The University of Sydney, Camperdown, New South Wales 2006, Australia
- Charles Perkins Centre, The University of Sydney, Camperdown, New South Wales 2006, Australia
| | - Juichien Hung
- School of Medical Sciences, Faculty of Health and Medicine, The University of Sydney, Camperdown, New South Wales 2006, Australia
- Charles Perkins Centre, The University of Sydney, Camperdown, New South Wales 2006, Australia
| | - Zihao Li
- School of Chemistry, Australian Centre for NanoMedicine, UNSW, Sydney, New South Wales 2052, Australia
| | - Kristopher A Kilian
- School of Chemistry, Australian Centre for NanoMedicine, UNSW, Sydney, New South Wales 2052, Australia
| | - Jelena Rnjak-Kovacina
- Graduate School of Biomedical Engineering, UNSW Australia, Sydney, New South Wales 2052, Australia
| | - Johannes B Pitts
- Technische Universität Braunschweig, Institute for Technical Chemistry, Braunschweig 38106, Germany
| | - Henning Menzel
- Technische Universität Braunschweig, Institute for Technical Chemistry, Braunschweig 38106, Germany
| | - Steven G Wise
- School of Medical Sciences, Faculty of Health and Medicine, The University of Sydney, Camperdown, New South Wales 2006, Australia
- Charles Perkins Centre, The University of Sydney, Camperdown, New South Wales 2006, Australia
- The University of Sydney Nano Institute, The University of Sydney, Camperdown, New South Wales 2006, Australia
| |
Collapse
|
13
|
Grant AJ, Yang N, Moore MJ, Lam YT, Michael PL, Chan AHP, Santos M, Rnjak-Kovacina J, Tan RP, Wise SG. Selective NLRP3 Inflammasome Inhibitor MCC950 Suppresses Inflammation and Facilitates Healing in Vascular Materials. Adv Sci (Weinh) 2023:e2300521. [PMID: 37150865 PMCID: PMC10369291 DOI: 10.1002/advs.202300521] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Subscribe] [Scholar Register] [Received: 01/24/2023] [Revised: 03/31/2023] [Indexed: 05/09/2023]
Abstract
Minimally invasive interventions using drug-eluting stents or balloons are a first-line treatment for certain occlusive cardiovascular diseases, but the major long-term cause of failure is neointimal hyperplasia (NIH). The drugs eluted from these devices are non-specific anti-proliferative drugs, such as paclitaxel (PTX) or sirolimus (SMS), which do not address the underlying inflammation. MCC950 is a selective inhibitor of the NLRP3-inflammasome, which drives sterile inflammation commonly observed in NIH. Additionally, in contrast to broad-spectrum anti-inflammatory drugs, MCC950 does not compromise global immune function due this selective activity. In this study, MCC950 is found to not impact the viability, integrity, or function of human coronary endothelial cells, in contrast to the non-specific anti-proliferative effects of PTX and SMS. Using an in vitro model of NLRP3-mediated inflammation in murine macrophages, MCC950 reduced IL-1β expression, which is a key driver of NIH. In an in vivo mouse model of NIH in vascular grafts, MCC950 significantly enhanced re-endothelialization and reduced NIH compared to PTX or SMS. These findings show the effectiveness of a targeted anti-inflammatory drug-elution strategy with significant implications for cardiovascular device intervention.
Collapse
Affiliation(s)
- Angus J Grant
- School of Medical Sciences, Faculty of Health and Medicine, Charles Perkins Centre, University of Sydney, Sydney, NSW, 2006, Australia
| | - Nianji Yang
- School of Medical Sciences, Faculty of Health and Medicine, Charles Perkins Centre, University of Sydney, Sydney, NSW, 2006, Australia
| | - Matthew J Moore
- School of Medical Sciences, Faculty of Health and Medicine, Charles Perkins Centre, University of Sydney, Sydney, NSW, 2006, Australia
| | - Yuen Ting Lam
- School of Medical Sciences, Faculty of Health and Medicine, Charles Perkins Centre, University of Sydney, Sydney, NSW, 2006, Australia
| | - Praveesuda L Michael
- School of Medical Sciences, Faculty of Health and Medicine, Charles Perkins Centre, University of Sydney, Sydney, NSW, 2006, Australia
| | - Alex H P Chan
- School of Medical Sciences, Faculty of Health and Medicine, Charles Perkins Centre, University of Sydney, Sydney, NSW, 2006, Australia
| | - Miguel Santos
- School of Medical Sciences, Faculty of Health and Medicine, Charles Perkins Centre, University of Sydney, Sydney, NSW, 2006, Australia
| | - Jelena Rnjak-Kovacina
- Graduate School of Biomedical Engineering, University of New South Wales, Sydney, NSW, 2006, Australia
| | - Richard P Tan
- School of Medical Sciences, Faculty of Health and Medicine, Charles Perkins Centre, University of Sydney, Sydney, NSW, 2006, Australia
| | - Steven G Wise
- School of Medical Sciences, Faculty of Health and Medicine, Charles Perkins Centre, University of Sydney, Sydney, NSW, 2006, Australia
| |
Collapse
|
14
|
Wei F, Mu Y, Tan RP, Wise SG, Bilek MM, Zhou Y, Xiao Y. Osteo-Immunomodulatory Role of Interleukin-4-Immobilized Plasma Immersion Ion Implantation Membranes for Bone Regeneration. ACS Appl Mater Interfaces 2023; 15:2590-2601. [PMID: 36607242 DOI: 10.1021/acsami.2c17005] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/17/2023]
Abstract
Barrier membranes for guided tissue regeneration are essential for bone repair and regeneration. The implanted membranes may trigger early inflammatory responses as a foreign material, which can affect the recruitment and differentiation of bone cells during tissue regeneration. The purpose of this study was to determine whether immobilizing interleukin 4 (IL4) on plasma immersion ion implantation (PIII)-activated surfaces may alter the osteo-immunoregulatory characteristics of the membranes and produce pro-osteogenic effects. In order to immobilize IL4, polycaprolactone surfaces were modified using the PIII technology. No discernible alterations were found between the morphology before and after PIII treatment or IL4 immobilization. IL4-immobilized PIII surfaces polarized macrophages to an M2 phenotype and mitigated inflammatory cytokine production under lipopolysaccharide stimulation. Interestingly, the co-culture of macrophages (on IL4-immobilized PIII surfaces) and bone marrow-derived mesenchymal stromal cells enhanced the production of angiogenic and osteogenic factors and triggered autophagy activation. Exosomes produced by PIII + IL4-stimulated macrophages were also found to play a role in osteoblast differentiation. In conclusion, the osteo-immunoregulatory properties of bone materials can be modified by PIII-assisted IL4 immobilization, creating a favorable osteoimmune milieu for bone regeneration.
Collapse
Affiliation(s)
- Fei Wei
- School of Mechanical, Medical and Process Engineering, Centre for Biomedical Technologies, Queensland University of Technology, Brisbane, Queensland 4000, Australia
- The Australia-China Centre for Tissue Engineering and Regenerative Medicine (ACCTERM), Brisbane, Queensland 4000, Australia
| | - Yuqing Mu
- School of Mechanical, Medical and Process Engineering, Centre for Biomedical Technologies, Queensland University of Technology, Brisbane, Queensland 4000, Australia
- School of Dentistry, Faculty of Health and Behavioural Sciences, The University of Queensland, Brisbane, Queensland 4006, Australia
- The Australia-China Centre for Tissue Engineering and Regenerative Medicine (ACCTERM), Brisbane, Queensland 4000, Australia
| | - Richard P Tan
- School of Medical Sciences, Faculty of Health and Medicine, The University of Sydney, Camperdown, New South Wales 2006, Australia
- Charles Perkins Centre, The University of Sydney, Camperdown, New South Wales 2006, Australia
| | - Steven G Wise
- School of Medical Sciences, Faculty of Health and Medicine, The University of Sydney, Camperdown, New South Wales 2006, Australia
- Charles Perkins Centre, The University of Sydney, Camperdown, New South Wales 2006, Australia
- Sydney Nano Institute, The University of Sydney, Camperdown, New South Wales 2006, Australia
| | - Marcela M Bilek
- Charles Perkins Centre, The University of Sydney, Camperdown, New South Wales 2006, Australia
- Sydney Nano Institute, The University of Sydney, Camperdown, New South Wales 2006, Australia
- School of Physics, The University of Sydney, Camperdown, New South Wales 2006, Australia
- School of Biomedical Engineering, The University of Sydney, Camperdown, New South Wales 2006, Australia
| | - Yinghong Zhou
- School of Mechanical, Medical and Process Engineering, Centre for Biomedical Technologies, Queensland University of Technology, Brisbane, Queensland 4000, Australia
- School of Dentistry, Faculty of Health and Behavioural Sciences, The University of Queensland, Brisbane, Queensland 4006, Australia
- The Australia-China Centre for Tissue Engineering and Regenerative Medicine (ACCTERM), Brisbane, Queensland 4000, Australia
| | - Yin Xiao
- School of Mechanical, Medical and Process Engineering, Centre for Biomedical Technologies, Queensland University of Technology, Brisbane, Queensland 4000, Australia
- The Australia-China Centre for Tissue Engineering and Regenerative Medicine (ACCTERM), Brisbane, Queensland 4000, Australia
- School of Medicine and Dentistry, Griffith University, Southport, Queensland 4222, Australia
| |
Collapse
|
15
|
Si Y, Zhang J, Bao S, Wise SG, Wang Y, Zhang Y, Tang Y. IL-32 and IL-34 in hepatocellular carcinoma. Front Med (Lausanne) 2022; 9:1051113. [DOI: 10.3389/fmed.2022.1051113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2022] [Accepted: 10/31/2022] [Indexed: 11/13/2022] Open
Abstract
Hepatocellular carcinoma (HCC) remains a major challenge to clinicians due to its unacceptably high mortality and morbidity. The etiology of HCC is multi-faceted, including viral infection, alcoholism and non-alcoholic fatty liver disease. Dysregulated host immunity contributes to tumorigenesis among these susceptible individuals with pre-existing condition(s). IL-32 and IL-34 are key cytokines driving the development of chronic inflammatory conditions such as rheumatoid arthritis, systemic lupus erythematosus, as well as chronic liver diseases. IL-32 and IL-34 play an important role augmenting the development of HCC, due to their direct influence over host inflammation, however, new roles for these cytokines in HCC are emerging. Here we comprehensively review the latest research for IL-32 and IL-34 in HCC, identifying a subset of potential therapeutic targets for use in precision medicine.
Collapse
|
16
|
Wang Q, Ma L, An C, Wise SG, Bao S. The role of IL-38 in intestinal diseases - its potential as a therapeutic target. Front Immunol 2022; 13:1051787. [PMID: 36405715 PMCID: PMC9670310 DOI: 10.3389/fimmu.2022.1051787] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2022] [Accepted: 10/20/2022] [Indexed: 11/06/2022] Open
Abstract
IL-38, an anti-inflammatory cytokine, is a key regulator of homeostasis in host immunity. Intestinal immunity plays a critical role in defence against pathogenic invasion, as it is the largest surface organ and the most common entry point for micro-organisms. Dysregulated IL-38 activity is observed in several autoimmune diseases including systemic lupus erythematosus and atherosclerosis. The protective role of IL-38 is well illustrated in experimental colitis models, showing significantly worse colitis in IL-38 deficient mice, compared to wildtype mice. Moreover, exogenous IL-38 has been shown to ameliorate experimental colitis. Surprisingly, upregulated IL-38 is detected in inflamed tissue from inflammatory bowel disease patients, consistent with increased circulating cytokine levels, demonstrating the complex nature of host immunity in vivo. However, colonic IL-38 is significantly reduced in malignant tissues from patients with colorectal cancer (CRC), compared to adjacent non-cancerous tissue. Additionally, IL-38 expression in CRC correlates with 5-year survival, tumour size and differentiation, suggesting IL-38 plays a protective role during the development of CRC. IL-38 is also an independent biomarker for the prognosis of CRC, offering useful information in the management of CRC. Taken together, these data demonstrate the role of IL-38 in the maintenance of normal intestinal mucosal homeostasis, but that dysregulation of IL-38 contributes to initiation of chronic inflammatory bowel disease (resulting from persistent local inflammation), and that IL-38 provides protection during the development of colorectal cancer. Such data provide useful information for the development of novel therapeutic targets in the management of intestinal diseases for more precise medicine.
Collapse
Affiliation(s)
- Qiang Wang
- Department of Anatomy, School of Basic Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu, China
| | - Linna Ma
- Department of Pathology, School of Basic Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu, China
| | - Caiping An
- Department of Haematology and Nephropathy, Gansu Provincial Hospital, Lanzhou, Gansu, China
- *Correspondence: Caiping An, ; Shisan Bao,
| | - Steven G. Wise
- School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia
| | - Shisan Bao
- Department of Anatomy, School of Basic Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu, China
- *Correspondence: Caiping An, ; Shisan Bao,
| |
Collapse
|
17
|
Mitchell TC, Feng NL, Lam YT, Michael P, Santos M, Wise SG. Engineering vascular bioreactor systems to closely mimic physiological forces in vitro. Tissue Engineering Part B: Reviews 2022. [DOI: 10.1089/ten.teb.2022.0158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- Timothy C Mitchell
- The University of Sydney, 4334, School of Medical Sciences, Sydney, New South Wales, Australia,
| | - Nicolas L Feng
- The University of Sydney, 4334, School of Medical Sciences, Sydney, New South Wales, Australia,
| | - Yuen Ting Lam
- The University of Sydney, 4334, School of Medical Sciences, Sydney, New South Wales, Australia,
| | - Praveesuda Michael
- The University of Sydney, 4334, School of Medical Sciences, Sydney, New South Wales, Australia,
| | - Miguel Santos
- The University of Sydney, 4334, School of Medical Sciences, Sydney, New South Wales, Australia,
| | - Steven G Wise
- The University of Sydney, 4334, School of Medical Sciences, Sydney, New South Wales, Australia,
| |
Collapse
|
18
|
Liu QH, Zhang JW, Xia L, Wise SG, Hambly BD, Tao K, Bao SS. Clinical implications of interleukins-31, 32, and 33 in gastric cancer. World J Gastrointest Oncol 2022; 14:1808-1822. [PMID: 36187404 PMCID: PMC9516641 DOI: 10.4251/wjgo.v14.i9.1808] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/28/2022] [Revised: 04/21/2022] [Accepted: 08/01/2022] [Indexed: 02/05/2023] Open
Abstract
BACKGROUND Gastric cancer (GC) is one of the most common malignancies in China with a high morbidity and mortality.
AIM To determine whether interleukin (IL)-31, IL-32, and IL-33 can be used as biomarkers for the detection of GC, via evaluating the correlations between their expression and clinicopathological parameters of GC patients.
METHODS Tissue array (n = 180) gastric specimens were utilised. IL-31, IL-32, and IL-33 expression in GC and non-GC tissues was detected immunohistochemically. The correlations between IL-31, IL-32, and IL-33 expression in GC and severity of clinicopathological parameters were evaluated. Survival curves were plotted using the Kaplan-Meier method/Cox regression. Circulating IL-31, IL-32, and IL-33 were detected by ELISA.
RESULTS We found that the expression levels of IL-31, IL-32, and IL-33 were all lower in GC than in adjacent non-GC gastric tissues (P < 0.05). IL-33 in peripheral blood of GC patients was significantly lower than that of healthy individuals (1.50 ± 1.11 vs 9.61 ± 8.00 ng/mL, P <0.05). Decreased IL-31, IL-32, and IL-33 in GC were observed in younger patients (< 60 years), and IL-32 and IL-33 were lower in female patients (P < 0.05). Higher IL-32 correlated with a longer survival in two GC subgroups: T4 invasion depth and TNM I-II stage. Univariate/multivariate analysis revealed that IL-32 was an independent prognostic factor for GC in the T4 stage subgroup. Circulating IL-33 was significantly lower in GC patients at TNM stage IV than in healthy people (P < 0.05).
CONCLUSION Our findings may provide new insights into the roles of IL-31, IL-32, and IL-33 in the carcinogenesis of GC and demonstrate their relative usefulness as prognostic markers for GC. The underlying mechanism of IL-31, IL-32, and IL-33 actions in GC should be further explored.
Collapse
Affiliation(s)
- Qing-Hua Liu
- Department of Pathology, Xuzhou Medical University, Xuzhou 221004, Jiangsu Province, China
| | - Ji-Wei Zhang
- Department of Surgery, The Central Hospital of Songjiang District, Shanghai Jiaotong University, Shanghai 201699, Shanghai, China
| | - Lei Xia
- Department of Pathology, Xuzhou Medical University, Xuzhou 221004, Jiangsu Province, China
| | - Steven G Wise
- Faculty of Medicine and Health, School of Medical Sciences, University of Sydney, Sydney 2006, NSW, Australia
| | | | - Kun Tao
- Department of Pathology,Tongren Hospital, Shanghai 200336, China
| | - Shi-San Bao
- Department of Pathology,Tongren Hospital, Shanghai 200336, China
| |
Collapse
|
19
|
Moore MJ, Tan RP, Yang N, Rnjak-Kovacina J, Wise SG. Bioengineering artificial blood vessels from natural materials. Trends Biotechnol 2021; 40:693-707. [PMID: 34887104 DOI: 10.1016/j.tibtech.2021.11.003] [Citation(s) in RCA: 28] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2021] [Revised: 11/10/2021] [Accepted: 11/11/2021] [Indexed: 01/22/2023]
Abstract
Bioengineering an effective, small diameter (<6 mm) artificial vascular graft for use in bypass surgery when autologous grafts are unavailable remains a persistent challenge. Commercially available grafts are typically made from plastics, which have high strength but lack elasticity and present a foreign surface that triggers undesirable biological responses. Tissue engineered grafts, leveraging decellularized animal vessels or derived de novo from long-term cell culture, have dominated recent research, but failed to meet clinical expectations. More effective constructs that are readily translatable are urgently needed. Recent advances in natural materials have made the production of robust acellular conduits feasible and their use increasingly attractive. Here, we identify a subset of natural materials with potential to generate durable, small diameter vascular grafts.
Collapse
Affiliation(s)
- Matthew J Moore
- School of Medical Sciences, Faculty of Health and Medicine, University of Sydney, NSW 2006, Australia; Charles Perkins Centre, University of Sydney, NSW 2006, Australia
| | - Richard P Tan
- School of Medical Sciences, Faculty of Health and Medicine, University of Sydney, NSW 2006, Australia; Charles Perkins Centre, University of Sydney, NSW 2006, Australia
| | - Nianji Yang
- School of Medical Sciences, Faculty of Health and Medicine, University of Sydney, NSW 2006, Australia; Charles Perkins Centre, University of Sydney, NSW 2006, Australia
| | - Jelena Rnjak-Kovacina
- Graduate School of Biomedical Engineering, UNSW Australia, Sydney, NSW 2052, Australia
| | - Steven G Wise
- School of Medical Sciences, Faculty of Health and Medicine, University of Sydney, NSW 2006, Australia; Charles Perkins Centre, University of Sydney, NSW 2006, Australia; The University of Sydney Nano Institute, University of Sydney, NSW 2006, Australia.
| |
Collapse
|
20
|
Tan RP, Ryder I, Yang N, Lam YT, Santos M, Michael PL, Robinson DA, Ng MK, Wise SG. Macrophage Polarization as a Novel Therapeutic Target for Endovascular Intervention in Peripheral Artery Disease. JACC Basic Transl Sci 2021; 6:693-704. [PMID: 34466756 PMCID: PMC8385566 DOI: 10.1016/j.jacbts.2021.04.008] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/08/2021] [Revised: 04/27/2021] [Accepted: 04/27/2021] [Indexed: 11/19/2022]
Abstract
Peripheral artery disease (PAD) has a significant impact on human health, affecting 200 million people globally. Advanced PAD severely diminishes quality of life, affecting mobility, and in its most severe form leads to limb amputation and death. Treatment of PAD is among the least effective of all endovascular procedures in terms of long-term efficacy. Chronic inflammation is a key driver of PAD; however, stents and coated balloons eluting antiproliferative drugs are most commonly used. As a result, neither stents nor coated balloons produce durable clinical outcomes in the superficial femoral artery, and both have recently been associated with significantly increased mortality. This review summarizes the most common clinical approaches and limitations to treating PAD and highlights the necessity to address the underlying causes of inflammation, identifying macrophages as a novel therapeutic target in the next generation of endovascular PAD intervention.
Collapse
Key Words
- BMS, bare-metal stent
- CAD, coronary artery disease
- DES, drug-eluting stent
- FP, femoropopliteal
- IL, interleukin
- MI, myocardial infarction
- PAD, peripheral artery disease
- PTA, percutaneous transluminal angioplasty
- SFA, superficial femoral artery
- TGF, transforming growth factor
- TNF, tumor necrosis factor
- drug-eluting balloon
- drug-eluting stent
- endovascular intervention
- macrophage polarization
- paclitaxel
- peripheral arterial disease
- vascular healing
- vascular inflammation
Collapse
Affiliation(s)
- Richard P. Tan
- Chronic Diseases, School of Medical Sciences, Faculty of Health and Medicine, University of Sydney, Sydney, New South Wales, Australia
- Charles Perkins Centre, University of Sydney, Sydney, New South Wales, Australia
- Address for correspondence: Dr. Richard P. Tan, Charles Perkins Centre, University of Sydney, Johns Hopkins Drive, Camperdown, Sydney, New South Wales 2006, Australia
| | - Isabelle Ryder
- Charles Perkins Centre, University of Sydney, Sydney, New South Wales, Australia
| | - Nianji Yang
- Chronic Diseases, School of Medical Sciences, Faculty of Health and Medicine, University of Sydney, Sydney, New South Wales, Australia
- Charles Perkins Centre, University of Sydney, Sydney, New South Wales, Australia
| | - Yuen Ting Lam
- Chronic Diseases, School of Medical Sciences, Faculty of Health and Medicine, University of Sydney, Sydney, New South Wales, Australia
- Charles Perkins Centre, University of Sydney, Sydney, New South Wales, Australia
| | - Miguel Santos
- Chronic Diseases, School of Medical Sciences, Faculty of Health and Medicine, University of Sydney, Sydney, New South Wales, Australia
- Charles Perkins Centre, University of Sydney, Sydney, New South Wales, Australia
| | - Praveesuda L. Michael
- Chronic Diseases, School of Medical Sciences, Faculty of Health and Medicine, University of Sydney, Sydney, New South Wales, Australia
- Charles Perkins Centre, University of Sydney, Sydney, New South Wales, Australia
| | - David A. Robinson
- Department of Vascular Surgery, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
| | - Martin K. Ng
- Department of Medicine, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
- Department of Cardiology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
| | - Steven G. Wise
- Chronic Diseases, School of Medical Sciences, Faculty of Health and Medicine, University of Sydney, Sydney, New South Wales, Australia
- Charles Perkins Centre, University of Sydney, Sydney, New South Wales, Australia
- University of Sydney Nano Institute, University of Sydney, Sydney, New South Wales, Australia
| |
Collapse
|
21
|
Yang N, Moore MJ, Michael PL, Santos M, Lam YT, Bao S, Ng MKC, Rnjak‐Kovacina J, Tan RP, Wise SG. Silk Fibroin Scaffold Architecture Regulates Inflammatory Responses and Engraftment of Bone Marrow-Mononuclear Cells. Adv Healthc Mater 2021; 10:e2100615. [PMID: 33963682 DOI: 10.1002/adhm.202100615] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2021] [Indexed: 12/13/2022]
Abstract
Despite being one of the most clinically trialed cell therapies, bone marrow-mononuclear cell (BM-MNC) infusion has largely failed to fulfill its clinical promise. Implanting biomimetic scaffolds at sites of injury prior to BM-MNC infusion is a promising approach to enhance BM-MNC engraftment and therapeutic function. Here, it is demonstrated that scaffold architecture can be leveraged to regulate the immune responses that drive BM-MNC engraftment. Silk scaffolds with thin fibers and low porosity (LP) impairs immune activation in vitro compared with thicker fiber, high porosity (HP) scaffolds. Using the authors' established in vivo bioluminescent BM-MNC tracking model, they showed that BM-MNCs home to and engraft in greater numbers in HP scaffolds over 14 days. Histological analysis reveals thicker fibrous capsule formation, with enhanced collagen deposition in HP compared to LP scaffolds consistent with substantially more native CD68+ macrophages and CD4+ T cells, driven by their elevated pro-inflammatory M1 and Th1 phenotypes, respectively. These results suggest that implant architecture impacts local inflammation that drives differential engraftment and remodeling behavior of infused BM-MNC. These findings inform the future design of biomimetic scaffolds that may better enhance the clinical effectiveness of BM-MNC infusion therapy.
Collapse
Affiliation(s)
- Nianji Yang
- School of Medical Sciences Faculty of Health and Medicine The University of Sydney Sydney NSW 2006 Australia
- Charles Perkins Centre The University of Sydney Sydney NSW 2006 Australia
| | - Matthew J. Moore
- School of Medical Sciences Faculty of Health and Medicine The University of Sydney Sydney NSW 2006 Australia
- Charles Perkins Centre The University of Sydney Sydney NSW 2006 Australia
| | - Praveesuda L. Michael
- School of Medical Sciences Faculty of Health and Medicine The University of Sydney Sydney NSW 2006 Australia
- Charles Perkins Centre The University of Sydney Sydney NSW 2006 Australia
| | - Miguel Santos
- School of Medical Sciences Faculty of Health and Medicine The University of Sydney Sydney NSW 2006 Australia
- Charles Perkins Centre The University of Sydney Sydney NSW 2006 Australia
| | - Yuen Ting Lam
- School of Medical Sciences Faculty of Health and Medicine The University of Sydney Sydney NSW 2006 Australia
- Charles Perkins Centre The University of Sydney Sydney NSW 2006 Australia
| | - Shisan Bao
- School of Medical Sciences Faculty of Health and Medicine The University of Sydney Sydney NSW 2006 Australia
- Charles Perkins Centre The University of Sydney Sydney NSW 2006 Australia
| | - Martin K. C. Ng
- Sydney Medical School The University of Sydney Sydney NSW 2006 Australia
- Department of Cardiology Royal Prince Alfred Hospital Sydney NSW 2042 Australia
| | - Jelena Rnjak‐Kovacina
- Graduate School of Biomedical Engineering University of New South Wales Sydney NSW 2052 Australia
| | - Richard P. Tan
- School of Medical Sciences Faculty of Health and Medicine The University of Sydney Sydney NSW 2006 Australia
- Charles Perkins Centre The University of Sydney Sydney NSW 2006 Australia
| | - Steven G. Wise
- School of Medical Sciences Faculty of Health and Medicine The University of Sydney Sydney NSW 2006 Australia
- Charles Perkins Centre The University of Sydney Sydney NSW 2006 Australia
- The University of Sydney Nano Institute (Sydney Nano) The University of Sydney Sydney NSW 2006 Australia
| |
Collapse
|
22
|
Michael PL, Lam YT, Hung J, Tan RP, Santos M, Wise SG. Comprehensive Evaluation of the Toxicity and Biosafety of Plasma Polymerized Nanoparticles. Nanomaterials (Basel) 2021; 11:nano11051176. [PMID: 33947114 PMCID: PMC8145910 DOI: 10.3390/nano11051176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/16/2021] [Revised: 04/22/2021] [Accepted: 04/23/2021] [Indexed: 11/17/2022]
Abstract
The rapid growth of nanoparticle-based therapeutics has underpinned significant developments in nanomedicine, which aim to overcome the limitations imposed by conventional therapies. Establishing the safety of new nanoparticle formulations is the first important step on the pathway to clinical translation. We have recently shown that plasma-polymerized nanoparticles (PPNs) are highly efficient nanocarriers and a viable, cost-effective alternative to conventional chemically synthesized nanoparticles. Here, we present the first comprehensive toxicity and biosafety study of PPNs using both established in vitro cell models and in vivo models. Overall, we show that PPNs were extremely well tolerated by all the cell types tested, significantly outperforming commercially available lipid-based nanoparticles (lipofectamine) used at the manufacturer’s recommended dosage. Supporting the in vitro data, the systemic toxicity of PPNs was negligible in BALB/c mice following acute and repeated tail-vein intravenous injections. PPNs were remarkably well tolerated in mice without any evidence of behavioral changes, weight loss, significant changes to the hematological profile, or signs of histological damage in tissues. PPNs were tolerated at extremely high doses without animal mortality observed at 6000 mg/kg and 48,000 mg/kg for acute and repeated-injection regimens, respectively. Our findings demonstrate the safety of PPNs in biological systems, adding to their future potential in biomedical applications.
Collapse
Affiliation(s)
- Praveesuda L. Michael
- Faculty of Health and Medicine, School of Medical Sciences, University of Sydney, Sydney, NSW 2006, Australia; (P.L.M.); (Y.T.L.); (J.H.); (R.P.T.)
- Charles Perkins Centre, University of Sydney, Sydney, NSW 2006, Australia
| | - Yuen Ting Lam
- Faculty of Health and Medicine, School of Medical Sciences, University of Sydney, Sydney, NSW 2006, Australia; (P.L.M.); (Y.T.L.); (J.H.); (R.P.T.)
- Charles Perkins Centre, University of Sydney, Sydney, NSW 2006, Australia
| | - Juichien Hung
- Faculty of Health and Medicine, School of Medical Sciences, University of Sydney, Sydney, NSW 2006, Australia; (P.L.M.); (Y.T.L.); (J.H.); (R.P.T.)
- Charles Perkins Centre, University of Sydney, Sydney, NSW 2006, Australia
| | - Richard P. Tan
- Faculty of Health and Medicine, School of Medical Sciences, University of Sydney, Sydney, NSW 2006, Australia; (P.L.M.); (Y.T.L.); (J.H.); (R.P.T.)
- Charles Perkins Centre, University of Sydney, Sydney, NSW 2006, Australia
| | - Miguel Santos
- Faculty of Health and Medicine, School of Medical Sciences, University of Sydney, Sydney, NSW 2006, Australia; (P.L.M.); (Y.T.L.); (J.H.); (R.P.T.)
- Charles Perkins Centre, University of Sydney, Sydney, NSW 2006, Australia
- Correspondence: (M.S.); (S.G.W.); Tel.: +61-2-8627-9458 (M.S.); +61-2-8627-9458 (S.G.W.)
| | - Steven G. Wise
- Faculty of Health and Medicine, School of Medical Sciences, University of Sydney, Sydney, NSW 2006, Australia; (P.L.M.); (Y.T.L.); (J.H.); (R.P.T.)
- Charles Perkins Centre, University of Sydney, Sydney, NSW 2006, Australia
- The University of Sydney Nano Institute (Sydney Nano), University of Sydney, Sydney, NSW 2006, Australia
- Correspondence: (M.S.); (S.G.W.); Tel.: +61-2-8627-9458 (M.S.); +61-2-8627-9458 (S.G.W.)
| |
Collapse
|
23
|
Tan RP, Hallahan N, Kosobrodova E, Michael PL, Wei F, Santos M, Lam YT, Chan AHP, Xiao Y, Bilek MMM, Thorn P, Wise SG. Bioactivation of Encapsulation Membranes Reduces Fibrosis and Enhances Cell Survival. ACS Appl Mater Interfaces 2020; 12:56908-56923. [PMID: 33314916 DOI: 10.1021/acsami.0c20096] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
Encapsulation devices are an emerging barrier technology designed to prevent the immunorejection of replacement cells in regenerative therapies for intractable diseases. However, traditional polymers used in current devices are poor substrates for cell attachment and induce fibrosis upon implantation, impacting long-term therapeutic cell viability. Bioactivation of polymer surfaces improves local host responses to materials, and here we make the first step toward demonstrating the utility of this approach to improve cell survival within encapsulation implants. Using therapeutic islet cells as an exemplar cell therapy, we show that internal surface coatings improve islet cell attachment and viability, while distinct external coatings modulate local foreign body responses. Using plasma surface functionalization (plasma immersion ion implantation (PIII)), we employ hollow fiber semiporous poly(ether sulfone) (PES) encapsulation membranes and coat the internal surfaces with the extracellular matrix protein fibronectin (FN) to enhance islet cell attachment. Separately, the external fiber surface is coated with the anti-inflammatory cytokine interleukin-4 (IL-4) to polarize local macrophages to an M2 (anti-inflammatory) phenotype, muting the fibrotic response. To demonstrate the power of our approach, bioluminescent murine islet cells were loaded into dual FN/IL-4-coated fibers and evaluated in a mouse back model for 14 days. Dual FN/IL-4 fibers showed striking reductions in immune cell accumulation and elevated levels of the M2 macrophage phenotype, consistent with the suppression of fibrotic encapsulation and enhanced angiogenesis. These changes led to markedly enhanced islet cell survival and importantly to functional integration of the implant with the host vasculature. Dual FN/IL-4 surface coatings drive multifaceted improvements in islet cell survival and function, with significant implications for improving clinical translation of therapeutic cell-containing macroencapsulation implants.
Collapse
Affiliation(s)
- Richard P Tan
- Department of Physiology, School of Medical Sciences, University of Sydney, Camperdown, NSW 2006, Australia
- Charles Perkins Centre, University of Sydney, John Hopkins Drive, Camperdown, NSW 2006, Australia
| | - Nicole Hallahan
- Department of Physiology, School of Medical Sciences, University of Sydney, Camperdown, NSW 2006, Australia
- Charles Perkins Centre, University of Sydney, John Hopkins Drive, Camperdown, NSW 2006, Australia
| | - Elena Kosobrodova
- Applied Plasma and Physics, A28, School of Physics, University of Sydney, Physics Road, Camperdown, NSW 2006, Australia
| | - Praveesuda L Michael
- Department of Physiology, School of Medical Sciences, University of Sydney, Camperdown, NSW 2006, Australia
- Charles Perkins Centre, University of Sydney, John Hopkins Drive, Camperdown, NSW 2006, Australia
| | - Fei Wei
- Institute of Health and Biomedical Innovation, Queensland University of Technology, 60 Musk Avenue, Kelvin Grove, QLD 4000, Australia
| | - Miguel Santos
- Department of Physiology, School of Medical Sciences, University of Sydney, Camperdown, NSW 2006, Australia
- Charles Perkins Centre, University of Sydney, John Hopkins Drive, Camperdown, NSW 2006, Australia
| | - Yuen Ting Lam
- Department of Physiology, School of Medical Sciences, University of Sydney, Camperdown, NSW 2006, Australia
- Charles Perkins Centre, University of Sydney, John Hopkins Drive, Camperdown, NSW 2006, Australia
| | - Alex H P Chan
- Department of Cardiothoracic Surgery, Stanford University, Stanford, CA 94305, United States
| | - Yin Xiao
- Institute of Health and Biomedical Innovation, Queensland University of Technology, 60 Musk Avenue, Kelvin Grove, QLD 4000, Australia
| | - Marcela M M Bilek
- Applied Plasma and Physics, A28, School of Physics, University of Sydney, Physics Road, Camperdown, NSW 2006, Australia
| | - Peter Thorn
- Department of Physiology, School of Medical Sciences, University of Sydney, Camperdown, NSW 2006, Australia
- Charles Perkins Centre, University of Sydney, John Hopkins Drive, Camperdown, NSW 2006, Australia
| | - Steven G Wise
- Department of Physiology, School of Medical Sciences, University of Sydney, Camperdown, NSW 2006, Australia
- Charles Perkins Centre, University of Sydney, John Hopkins Drive, Camperdown, NSW 2006, Australia
| |
Collapse
|
24
|
Cui X, Soliman BG, Alcala-Orozco CR, Li J, Vis MAM, Santos M, Wise SG, Levato R, Malda J, Woodfield TBF, Rnjak-Kovacina J, Lim KS. Rapid Photocrosslinking of Silk Hydrogels with High Cell Density and Enhanced Shape Fidelity. Adv Healthc Mater 2020; 9:e2001801. [PMID: 33205605 DOI: 10.1002/adhm.202001801] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
25
|
Climie RE, Wu JHY, Calkin AC, Chapman N, Inglis SC, Mirabito Colafella KM, Picone DS, Tan JTM, Thomas E, Viola HM, Wise SG, Murphy AJ, Nelson MR, Nicholls SJ, Hool LC, Doyle K, Figtree GA, Marques FZ. Lack of Strategic Funding and Long-Term Job Security Threaten to Have Profound Effects on Cardiovascular Researcher Retention in Australia. Heart Lung Circ 2020; 29:1588-1595. [PMID: 32839116 PMCID: PMC7442027 DOI: 10.1016/j.hlc.2020.07.010] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2020] [Revised: 07/08/2020] [Accepted: 07/24/2020] [Indexed: 01/24/2023]
Abstract
Background Cardiovascular disease is the leading cause of death in Australia. Investment in research solutions has been demonstrated to yield health and a 9.8-fold return economic benefit. The sector, however, is severely challenged with success rates of traditional peer-reviewed funding in decline. Here, we aimed to understand the perceived challenges faced by the cardiovascular workforce in Australia prior to the COVID-19 pandemic. Methods We used an online survey distributed across Australian cardiovascular societies/councils, universities and research institutes over a period of 6 months during 2019, with 548 completed responses. Inclusion criteria included being an Australian resident or an Australian citizen who lived overseas, and a current or past student or employee in the field of cardiovascular research. Results The mean age of respondents was 42±13 years, 47% were male, 85% had a full-time position, and 40% were a group leader or laboratory head. Twenty-three per cent (23%) had permanent employment, and 82% of full-time workers regularly worked >40 hours/week. Sixty-eight per cent (68%) said they had previously considered leaving the cardiovascular research sector. If their position could not be funded in the next few years, a staggering 91% of respondents would leave the sector. Compared to PhD- and age-matched men, women were less likely to be a laboratory head and to feel they had a long-term career path as a cardiovascular researcher, while more women were unsure about future employment and had considered leaving the sector (all p<0.05). Greater job security (76%) and government and philanthropic investment in cardiovascular research (72%) were highlighted by responders as the main changes to current practices that would encourage them to stay. Conclusion Strategic solutions, such as diversification of career pathways and funding sources, and moving from a competitive to a collaborative culture, need to be a priority to decrease reliance on government funding and allow cardiovascular researchers to thrive.
Collapse
Affiliation(s)
- Rachel E Climie
- Sports Cardiology and Diabetes and Population Health Laboratories, Baker Heart and Diabetes Institute, Melbourne, Vic, Australia; Menzies Institute for Medical Research, University of Tasmania, Hobart, Tas, Australia
| | - Jason H Y Wu
- The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia
| | - Anna C Calkin
- Central Clinical School, Monash University, Melbourne, Vic, Australia; Lipid Metabolism and Cardiometabolic Disease, Baker Heart and Diabetes Institute, Melbourne, Vic, Australia
| | - Niamh Chapman
- Menzies Institute for Medical Research, University of Tasmania, Hobart, Tas, Australia
| | - Sally C Inglis
- IMPACCT, Faculty of Health, University of Technology Sydney, Sydney, NSW, Australia
| | | | - Dean S Picone
- Menzies Institute for Medical Research, University of Tasmania, Hobart, Tas, Australia
| | - Joanne T M Tan
- Vascular Research Centre, Lifelong Health Theme, South Australian Health & Medical Research Institute, Adelaide, SA, Australia; Adelaide Medical School, The University of Adelaide, Adelaide, SA, Australia
| | - Emma Thomas
- Centre for Online Health, Centre for Health Services Research, The University of Queensland, Brisbane, Qld, Australia
| | - Helena M Viola
- School of Human Sciences, The University of Western Australia, Perth, WA, Australia
| | - Steven G Wise
- School of Medical Sciences, Department of Physiology, University of Sydney, Sydney, NSW, Australia
| | - Andrew J Murphy
- Haematopoiesis and Leukocyte Biology, Baker Heart and Diabetes Institute, Melbourne, Vic, Australia
| | - Mark R Nelson
- Menzies Institute for Medical Research, University of Tasmania, Hobart, Tas, Australia
| | - Stephen J Nicholls
- Monash Cardiovascular Research Centre, Monash University, Melbourne, Vic, Australia
| | - Livia C Hool
- School of Human Sciences, The University of Western Australia, Perth, WA, Australia; Victor Chang Cardiac Research Institute, Sydney, NSW, Australia
| | - Kerry Doyle
- Australian Cardiovascular Alliance, Sydney, NSW, Australia
| | - Gemma A Figtree
- Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia
| | - Francine Z Marques
- Hypertension Research Laboratory, School of Biological Sciences, Faculty of Science, Monash University, Melbourne, Vic, Australia; Baker Heart and Diabetes Institute, Melbourne, Vic, Australia.
| | | |
Collapse
|
26
|
Lam YT, Hsu CJ, Simpson PJL, Dunn LL, Chow RW, Chan KH, Yong ASC, Yu Y, Sieveking DP, Lecce L, Yuan J, Celermajer DS, Wise SG, Ng MKC. Androgens Stimulate EPC-Mediated Neovascularization and Are Associated with Increased Coronary Collateralization. Endocrinology 2020; 161:5802765. [PMID: 32157309 DOI: 10.1210/endocr/bqaa043] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/08/2019] [Accepted: 03/05/2020] [Indexed: 11/19/2022]
Abstract
Endothelial progenitor cells (EPCs) play a key role in neovascularization and have been linked to improved cardiovascular outcomes. Although there is a well-established inverse relationship between androgen levels and cardiovascular mortality in men, the role of androgens in EPC function is not fully understood. In this study, we investigated the effects of androgens on 2 subpopulations of EPCs, early EPCs (EEPCs) and late outgrowth EPCs (OECs), and their relationships with coronary collateralization. Early EPCs and OECs were isolated from the peripheral blood of young healthy men and treated with dihydrotestosterone (DHT) with or without androgen receptor (AR) antagonist, hydroxyflutamide, in vitro. Dihydrotestosterone treatment enhanced AR-mediated proliferation, migration, and tubulogenesis of EEPCs and OECs in a dose-dependent manner. Furthermore, DHT augmented EPC sensitivity to extracellular stimulation by vascular endothelial growth factor (VEGF) via increased surface VEGF receptor expression and AKT activation. In vivo, xenotransplantation of DHT pretreated human EPCs augmented blood flow recovery and angiogenesis in BALB/c nude male mice, compared to mice receiving untreated EPCs, following hindlimb ischemia. In particular, DHT pretreated human OECs exhibited higher reparative potential than EEPCs in augmenting postischemic blood flow recovery in mice. Furthermore, whole blood was collected from the coronary sinus of men with single vessel coronary artery disease (CAD) who underwent elective percutaneous intervention (n = 23). Coronary collateralization was assessed using the collateral flow index. Serum testosterone and EPC levels were measured. In men with CAD, circulating testosterone was positively associated with the extent of coronary collateralization and the levels of OECs. In conclusion, androgens enhance EPC function and promote neovascularization after ischemia in mice and are associated with coronary collateralization in men.
Collapse
Affiliation(s)
- Yuen Ting Lam
- School of Medical Science, Faculty of Health and Medicine, University of Sydney, Sydney, Australia
| | | | | | | | | | - Kim H Chan
- School of Medical Science, Faculty of Health and Medicine, University of Sydney, Sydney, Australia
- Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia
| | - Andy S C Yong
- Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia
| | - Young Yu
- Heart Research Institute, Sydney, Australia
| | | | | | - Jun Yuan
- Heart Research Institute, Sydney, Australia
| | - David S Celermajer
- School of Medical Science, Faculty of Health and Medicine, University of Sydney, Sydney, Australia
- Heart Research Institute, Sydney, Australia
- Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia
| | - Steven G Wise
- School of Medical Science, Faculty of Health and Medicine, University of Sydney, Sydney, Australia
| | - Martin K C Ng
- School of Medical Science, Faculty of Health and Medicine, University of Sydney, Sydney, Australia
- Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia
| |
Collapse
|
27
|
Cui X, Soliman BG, Alcala‐Orozco CR, Li J, Vis MAM, Santos M, Wise SG, Levato R, Malda J, Woodfield TBF, Rnjak‐Kovacina J, Lim KS. Rapid Photocrosslinking of Silk Hydrogels with High Cell Density and Enhanced Shape Fidelity. Adv Healthc Mater 2020; 9:e1901667. [PMID: 31943911 DOI: 10.1002/adhm.201901667] [Citation(s) in RCA: 58] [Impact Index Per Article: 14.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2019] [Revised: 12/12/2019] [Indexed: 12/14/2022]
Abstract
Silk fibroin hydrogels crosslinked through di-tyrosine bonds are clear, elastomeric constructs with immense potential in regenerative medicine applications. In this study, demonstrated is a new visible light-mediated photoredox system for di-tyrosine bond formation in silk fibroin that overcomes major limitations of current conventional enzymatic-based crosslinking. This photomediated system rapidly crosslinks silk fibroin (<1 min), allowing encapsulation of cells at significantly higher cell densities (15 million cells mL-1 ) while retaining high cell viability (>80%). The photocrosslinked silk hydrogels present more stable mechanical properties which do not undergo spontaneous transition to stiff, β-sheet-rich networks typically seen for enzymatically crosslinked systems. These hydrogels also support long-term culture of human articular chondrocytes, with excellent cartilage tissue formation. This system also facilitates the first demonstration of biofabrication of silk fibroin constructs in the absence of chemical modification of the protein structure or rheological additives. Cell-laden constructs with complex, ordered, graduated architectures, and high resolution (40 µm) are fabricated using the photocrosslinking system, which cannot be achieved using the enzymatic crosslinking system. Taken together, this work demonstrates the immense potential of a new crosslinking approach for fabrication of elastomeric silk hydrogels with applications in biofabrication and tissue regeneration.
Collapse
Affiliation(s)
- Xiaolin Cui
- Christchurch Regenerative Medicine and Tissue Engineering (CReaTE) Group Department of Orthopaedics Surgery and Musculoskeletal Medicine University of Otago Christchurch 8011 New Zealand
- Medical Technologies Centre of Research Excellence Auckland 1010 New Zealand
| | - Bram G. Soliman
- Christchurch Regenerative Medicine and Tissue Engineering (CReaTE) Group Department of Orthopaedics Surgery and Musculoskeletal Medicine University of Otago Christchurch 8011 New Zealand
| | - Cesar R. Alcala‐Orozco
- Christchurch Regenerative Medicine and Tissue Engineering (CReaTE) Group Department of Orthopaedics Surgery and Musculoskeletal Medicine University of Otago Christchurch 8011 New Zealand
| | - Jun Li
- Christchurch Regenerative Medicine and Tissue Engineering (CReaTE) Group Department of Orthopaedics Surgery and Musculoskeletal Medicine University of Otago Christchurch 8011 New Zealand
| | - Michelle A. M. Vis
- Christchurch Regenerative Medicine and Tissue Engineering (CReaTE) Group Department of Orthopaedics Surgery and Musculoskeletal Medicine University of Otago Christchurch 8011 New Zealand
| | - Miguel Santos
- School of Medical Sciences Department of Physiology University of Sydney Camperdown NSW 2006 Australia
- Charles Perkins Centre University of Sydney Camperdown NSW 2006 Australia
| | - Steven G. Wise
- School of Medical Sciences Department of Physiology University of Sydney Camperdown NSW 2006 Australia
- Charles Perkins Centre University of Sydney Camperdown NSW 2006 Australia
| | - Riccardo Levato
- Regenerative Medicine Center Utrecht Heidelberglaan 100 3584 CX Utrecht The Netherlands
- Department of Orthopaedics University Medical Center Utrecht Heidelberglaan 100 3584 CX Utrecht The Netherlands
| | - Jos Malda
- Regenerative Medicine Center Utrecht Heidelberglaan 100 3584 CX Utrecht The Netherlands
- Department of Orthopaedics University Medical Center Utrecht Heidelberglaan 100 3584 CX Utrecht The Netherlands
- Department of Equine Sciences Faculty of Veterinary Medicine Utrecht University Domplein 29 3512 JE Utrecht The Netherlands
| | - Tim B. F. Woodfield
- Christchurch Regenerative Medicine and Tissue Engineering (CReaTE) Group Department of Orthopaedics Surgery and Musculoskeletal Medicine University of Otago Christchurch 8011 New Zealand
- Medical Technologies Centre of Research Excellence Auckland 1010 New Zealand
- Maurice Wilkins Centre for Molecular Biodiscovery Auckland 1010 New Zealand
| | - Jelena Rnjak‐Kovacina
- Graduate School of Biomedical Engineering University of New South Wales Sydney 2052 Australia
| | - Khoon S. Lim
- Christchurch Regenerative Medicine and Tissue Engineering (CReaTE) Group Department of Orthopaedics Surgery and Musculoskeletal Medicine University of Otago Christchurch 8011 New Zealand
- Medical Technologies Centre of Research Excellence Auckland 1010 New Zealand
- Maurice Wilkins Centre for Molecular Biodiscovery Auckland 1010 New Zealand
| |
Collapse
|
28
|
Yang N, Tan RP, Chan AHP, Lee BSL, Santos M, Hung J, Liao Y, Bilek MMM, Fei J, Wise SG, Bao S. Immobilized Macrophage Colony-Stimulating Factor (M-CSF) Regulates the Foreign Body Response to Implanted Materials. ACS Biomater Sci Eng 2020; 6:995-1007. [PMID: 33464851 DOI: 10.1021/acsbiomaterials.9b01887] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
The functionality and durability of implanted biomaterials are often compromised by an exaggerated foreign body reaction (FBR). M1/M2 polarization of macrophages is a critical regulator of scaffold-induced FBR. Macrophage colony-stimulating factor (M-CSF), a hematopoietic growth factor, induces macrophages into an M2-like polarized state, leading to immunoregulation and promoting tissue repair. In the present study, we explored the immunomodulatory effects of surface bound M-CSF on poly-l-lactic acid (PLLA)-induced FBR. M-CSF was immobilized on the surface of PLLA via plasma immersion ion implantation (PIII). M-CSF functionalized PLLA, PLLA-only, and PLLA+PIII were assessed in an IL-1β luciferase reporter mouse to detect real-time levels of IL-1β expression, reflecting acute inflammation in vivo. Additionally, these different treated scaffolds were implanted subcutaneously into wild-type mice to explore the effect of M-CSF in polarization of M2-like macrophages (CD68+/CD206+), related cytokines (pro-inflammatory: IL-1β, TNF and MCP-1; anti-inflammatory: IL-10 and TGF-β), and angiogenesis (CD31) by immunofluorescent staining. Our data demonstrated that IL-1β activity in M-CSF functionalized scaffolds was ∼50% reduced compared to PLLA-only at day 1 (p < 0.01) and day 2 (p < 0.05) post-implantation. There were >2.6-fold more CD206+ macrophages in M-CSF functionalized PLLA compared to PLLA-only at day 7 (p < 0.001), along with higher levels of IL-10 at both day 7 (p < 0.05) and day 14 (p < 0.01), and TGF-β at day 3 (p < 0.05), day 7 (p < 0.05), and day 14 (p < 0.001). Lower levels of pro-inflammatory cytokines were also detected in M-CSF functionalized PLLA in the early phase of the immune response compared to PLLA-only: a ∼58% decrease at day 3 in IL-1β; a ∼91% decrease at day 3 and a ∼66% decrease at day 7 in TNF; and a ∼60% decrease at day 7 in MCP-1. Moreover, enhanced angiogenesis inside and on/near the scaffold was observed in M-CSF functionalized PLLA compared to PLLA-only at day 3 (p < 0.05) and day 7 (p < 0.05), respectively. Overall, M-CSF functionalized PLLA enhanced CD206+ macrophage polarization and angiogenesis, consistent with lower levels of pro-inflammatory cytokines and higher levels of anti-inflammatory cytokines in early stages of the host response, indicating potential immunoregulatory functions on the local environment.
Collapse
Affiliation(s)
- Nianji Yang
- Discipline of Pathology, University of Sydney, Sydney, New South Wales 2006, Australia.,Discipline of Physiology, University of Sydney, Sydney, New South Wales 2006, Australia.,The Heart Research Institute, Sydney, Australia.,Charles Perkins Centre, University of Sydney, Sydney, New South Wales 2006, Australia
| | - Richard P Tan
- Discipline of Physiology, University of Sydney, Sydney, New South Wales 2006, Australia.,The Heart Research Institute, Sydney, Australia.,Charles Perkins Centre, University of Sydney, Sydney, New South Wales 2006, Australia
| | | | - Bob S L Lee
- Discipline of Physiology, University of Sydney, Sydney, New South Wales 2006, Australia.,The Heart Research Institute, Sydney, Australia.,Charles Perkins Centre, University of Sydney, Sydney, New South Wales 2006, Australia
| | - Miguel Santos
- Discipline of Physiology, University of Sydney, Sydney, New South Wales 2006, Australia.,The Heart Research Institute, Sydney, Australia.,Charles Perkins Centre, University of Sydney, Sydney, New South Wales 2006, Australia
| | - Juichien Hung
- Discipline of Physiology, University of Sydney, Sydney, New South Wales 2006, Australia.,The Heart Research Institute, Sydney, Australia.,Charles Perkins Centre, University of Sydney, Sydney, New South Wales 2006, Australia
| | - Yun Liao
- Department of Pharmacy, Tongren Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - Marcela M M Bilek
- Charles Perkins Centre, University of Sydney, Sydney, New South Wales 2006, Australia.,School of Physics, University of Sydney, Sydney, New South Wales 2006, Australia
| | - Jian Fei
- School of Life Science and Technology, Shanghai Tongji University, Shanghai, China.,Research Centre for Model Organism, Shanghai, China
| | - Steven G Wise
- Discipline of Physiology, University of Sydney, Sydney, New South Wales 2006, Australia.,The Heart Research Institute, Sydney, Australia.,Charles Perkins Centre, University of Sydney, Sydney, New South Wales 2006, Australia
| | - Shisan Bao
- Discipline of Pathology, University of Sydney, Sydney, New South Wales 2006, Australia.,Charles Perkins Centre, University of Sydney, Sydney, New South Wales 2006, Australia
| |
Collapse
|
29
|
Chan AHP, Filipe EC, Tan RP, Santos M, Yang N, Hung J, Feng J, Nazir S, Benn AJ, Ng MKC, Rnjak-Kovacina J, Wise SG. Altered processing enhances the efficacy of small-diameter silk fibroin vascular grafts. Sci Rep 2019; 9:17461. [PMID: 31767928 PMCID: PMC6877724 DOI: 10.1038/s41598-019-53972-y] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2019] [Accepted: 11/06/2019] [Indexed: 01/24/2023] Open
Abstract
Current synthetic vascular grafts are not suitable for use in low-diameter applications. Silk fibroin is a promising natural graft material which may be an effective alternative. In this study, we compared two electrospun silk grafts with different manufacturing processes, using either water or hexafluoroisopropanol (HFIP) as solvent. This resulted in markedly different Young's modulus, ultimate tensile strength and burst pressure, with HFIP spun grafts observed to have thicker fibres, and greater stiffness and strength relative to water spun. Assessment in a rat abdominal aorta grafting model showed significantly faster endothelialisation of the HFIP spun graft relative to water spun. Neointimal hyperplasia in the HFIP graft also stabilised significantly earlier, correlated with an earlier SMC phenotype switch from synthetic to contractile, increasing extracellular matrix protein density. An initial examination of the macrophage response showed that HFIP spun conduits promoted an anti-inflammatory M2 phenotype at early timepoints while reducing the pro-inflammatory M1 phenotype relative to water spun grafts. These observations demonstrate the important role of the manufacturing process and physical graft properties in determining the physiological response. Our study is the first to comprehensively study these differences for silk in a long-term rodent model.
Collapse
Affiliation(s)
- Alex H P Chan
- The Heart Research Institute, 7 Eliza Street, Newtown, Sydney, NSW, 2042, Australia.,Sydney Medical School, University of Sydney, Sydney, NSW, 2006, Australia
| | - Elysse C Filipe
- Garvan Institute of Medical Research & The Kinghorn Cancer Center, Sydney, NSW, 2010, Australia.,St Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, NSW, 2010, Australia
| | - Richard P Tan
- The Heart Research Institute, 7 Eliza Street, Newtown, Sydney, NSW, 2042, Australia.,Sydney Medical School, University of Sydney, Sydney, NSW, 2006, Australia
| | - Miguel Santos
- The Heart Research Institute, 7 Eliza Street, Newtown, Sydney, NSW, 2042, Australia.,Sydney Medical School, University of Sydney, Sydney, NSW, 2006, Australia
| | - Nianji Yang
- The Heart Research Institute, 7 Eliza Street, Newtown, Sydney, NSW, 2042, Australia
| | - Juichien Hung
- The Heart Research Institute, 7 Eliza Street, Newtown, Sydney, NSW, 2042, Australia
| | - Jieyao Feng
- The Heart Research Institute, 7 Eliza Street, Newtown, Sydney, NSW, 2042, Australia
| | - Sidra Nazir
- The Heart Research Institute, 7 Eliza Street, Newtown, Sydney, NSW, 2042, Australia
| | - Alexander J Benn
- The Heart Research Institute, 7 Eliza Street, Newtown, Sydney, NSW, 2042, Australia
| | - Martin K C Ng
- Sydney Medical School, University of Sydney, Sydney, NSW, 2006, Australia.,Department of Cardiology, Royal Prince Alfred Hospital, Camperdown, Sydney, NSW, 2050, Australia
| | - Jelena Rnjak-Kovacina
- Graduate School of Biomedical Engineering, UNSW Sydney, Sydney, NSW, 2052, Australia.
| | - Steven G Wise
- The Heart Research Institute, 7 Eliza Street, Newtown, Sydney, NSW, 2042, Australia. .,Sydney Medical School, University of Sydney, Sydney, NSW, 2006, Australia. .,School of Medical Sciences, Dept of Physiology, University of Sydney, Sydney, NSW, 2006, Australia. .,Charles Perkins Centre, University of Sydney, Sydney, NSW, 2006, Australia.
| |
Collapse
|
30
|
Lam YT, Lecce L, Yuen SC, Wise SG, Handelsman DJ, Karas RH, Ng MKC. Androgens Ameliorate Impaired Ischemia-Induced Neovascularization Due to Aging in Male Mice. Endocrinology 2019; 160:1137-1149. [PMID: 30830222 DOI: 10.1210/en.2018-00951] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/08/2018] [Accepted: 02/26/2019] [Indexed: 11/19/2022]
Abstract
There is abundant evidence that low circulating testosterone levels in older men are associated with adverse cardiovascular outcomes; however, the direction of causality is unclear. Although there is burgeoning interest in the potential of androgen therapy in older men, the effect of androgens on cardiovascular regeneration in aging males remains poorly defined. We investigated the role of androgens in age-related impairment in ischemia-induced neovascularization. Castrated young (2 months) and old (24 months) male mice were subjected to unilateral hindlimb ischemia and treated with subdermal DHT or placebo Silastic implants. Blood flow recovery was enhanced by DHT treatment in young and old mice compared with age-matched placebo controls. DHT augmented angiogenesis in young mice and ameliorated age-related impairment in neovascularization in old mice. Administration of DHT was associated with increased hypoxia inducible factor-1α (HIF-1α) and stromal cell‒derived factor-1 expression in young mice, but not in old mice. In vitro, DHT-induced HIF-1α transcriptional activation was attenuated in fibroblasts from old mice. Interaction between androgen receptor (AR) and importins, key proteins that facilitate nuclear translocation of AR, was impaired with age. In contrast, DHT treatment stimulated the production and mobilization of Sca1+/CXCR4+ circulating progenitor cells in both young and old mice. DHT stimulated the migration and proangiogenic paracrine effect of ex vivo cultured bone marrow‒derived angiogenic cells from young and old mice. In conclusion, androgens ameliorated age-related impairment in ischemia-induced neovascularization. Although age-dependent dysfunction in androgen signaling attenuated some androgen effects on angiogenesis, provasculogenic effects of androgens were partially preserved with age.
Collapse
Affiliation(s)
- Yuen Ting Lam
- The Heart Research Institute, Newtown, New South Wales, Australia
- Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | - Laura Lecce
- The Zena and Michael A. Wiener Cardiovascular Institute and Cardiovascular Research Center, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Sui Ching Yuen
- The Heart Research Institute, Newtown, New South Wales, Australia
- Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | - Steven G Wise
- The Heart Research Institute, Newtown, New South Wales, Australia
- Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | - David J Handelsman
- ANZAC Research Institute, University of Sydney, Concord Hospital, Sydney, New South Wales, Australia
| | - Richard H Karas
- The Molecular Cardiology Research Institute, Tufts Medical Center, Boston, Massachusetts
| | - Martin K C Ng
- The Heart Research Institute, Newtown, New South Wales, Australia
- Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
- Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
| |
Collapse
|
31
|
Tan RP, Chan AH, Wei S, Santos M, Lee BS, Filipe EC, Akhavan B, Bilek MM, Ng MK, Xiao Y, Wise SG. Bioactive Materials Facilitating Targeted Local Modulation of Inflammation. JACC Basic Transl Sci 2019; 4:56-71. [PMID: 30847420 PMCID: PMC6390730 DOI: 10.1016/j.jacbts.2018.10.004] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/10/2018] [Revised: 10/10/2018] [Accepted: 10/12/2018] [Indexed: 11/02/2022]
Abstract
Cardiovascular disease is an inflammatory disorder that may benefit from appropriate modulation of inflammation. Systemic treatments lower cardiac events but have serious adverse effects. Localized modulation of inflammation in current standard treatments such as bypass grafting may more effectively treat CAD. The present study investigated a bioactive vascular graft coated with the macrophage polarizing cytokine interleukin-4. These grafts repolarize macrophages to anti-inflammatory phenotypes, leading to modulation of the pro-inflammatory microenvironment and ultimately to a reduction of foreign body encapsulation and inhibition of neointimal hyperplasia development. These resulting functional improvements have significant implications for the next generation of synthetic vascular grafts.
Collapse
Affiliation(s)
- Richard P. Tan
- Heart Research Institute, Sydney, New South Wales, Australia
- Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | - Alex H.P. Chan
- Heart Research Institute, Sydney, New South Wales, Australia
- Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | - Simon Wei
- Science and Engineering Faculty, Queensland University of Technology, Brisbane, Queensland, Australia
| | - Miguel Santos
- Heart Research Institute, Sydney, New South Wales, Australia
- School of Physics, University of Sydney, Sydney, New South Wales, Australia
| | - Bob S.L. Lee
- Heart Research Institute, Sydney, New South Wales, Australia
- Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | - Elysse C. Filipe
- Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
- Garvan Institute of Medical Research, Cancer Division, Sydney, New South Wales, Australia
| | - Behnam Akhavan
- Heart Research Institute, Sydney, New South Wales, Australia
- School of Physics, University of Sydney, Sydney, New South Wales, Australia
- School of Aerospace, Mechanical and Mechatronic Engineering, University of Sydney, Sydney, New South Wales, Australia
| | - Marcela M. Bilek
- School of Physics, University of Sydney, Sydney, New South Wales, Australia
- School of Aerospace, Mechanical and Mechatronic Engineering, University of Sydney, Sydney, New South Wales, Australia
- Charles Perkins Centre, University of Sydney, Sydney, New South Wales, Australia
- Sydney Nano Institute, University of Sydney, Sydney, New South Wales, Australia
| | - Martin K.C. Ng
- Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
- Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
| | - Yin Xiao
- Science and Engineering Faculty, Queensland University of Technology, Brisbane, Queensland, Australia
| | - Steven G. Wise
- Heart Research Institute, Sydney, New South Wales, Australia
- Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| |
Collapse
|
32
|
Biglari S, Le TYL, Tan RP, Wise SG, Zambon A, Codolo G, De Bernard M, Warkiani M, Schindeler A, Naficy S, Valtchev P, Khademhosseini A, Dehghani F. Simulating Inflammation in a Wound Microenvironment Using a Dermal Wound-on-a-Chip Model. Adv Healthc Mater 2019; 8:e1801307. [PMID: 30511808 DOI: 10.1002/adhm.201801307] [Citation(s) in RCA: 35] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2018] [Revised: 11/14/2018] [Indexed: 11/12/2022]
Abstract
Considerable progress has been made in the field of microfluidics to develop complex systems for modeling human skin and dermal wound healing processes. While microfluidic models have attempted to integrate multiple cell types and/or 3D culture systems, to date they have lacked some elements needed to fully represent dermal wound healing. This paper describes a cost-effective, multicellular microfluidic system that mimics the paracrine component of early inflammation close to normal wound healing. Collagen and Matrigel are tested as materials for coating and adhesion of dermal fibroblasts and human umbilical vein endothelial cells (HUVECs). The wound-on-chip model consists of three interconnecting channels and is able to simulate wound inflammation by adding tumor necrosis factor alpha (TNF-α) or by triculturing with macrophages. Both the approaches significantly increase IL-1β, IL-6, IL-8 in the supernatant (p < 0.05), and increases in cytokine levels are attenuated by cotreatment with an anti-inflammatory agent, Dexamethasone. Incorporation of M1 and M2 macrophages cocultured with fibroblasts and HUVECs leads to a stimulation of cytokine production as well as vascular structure formation, particularly with M2 macrophages. In summary, this wound-on-chip system can be used to model the paracrine component of the early inflammatory phase of wound healing and has the potential for the screening of anti-inflammatory compounds.
Collapse
Affiliation(s)
- Sahar Biglari
- School of Chemical Biomolecular Engineering University of Sydney Sydney 2006 Australia
| | - Thi Y. L. Le
- School of Chemical Biomolecular Engineering University of Sydney Sydney 2006 Australia
| | | | - Steven G. Wise
- Heart Research Institute Sydney 2042 Australia
- Sydney Medical School University of Sydney Sydney 2006 Australia
| | - Alessandro Zambon
- Department of Industrial Engineering University of Padua Padua 35122 Italy
| | - Gaia Codolo
- Department of Biology University of Padua Padua 35122 Italy
| | | | - Majid Warkiani
- School of Biomedical Engineering University Technology of Sydney Sydney 2007 Australia
| | - Aaron Schindeler
- School of Chemical Biomolecular Engineering University of Sydney Sydney 2006 Australia
- Orthopedic Research & Biotechnology Unit The Children's Hospital at Westmead Westmead 2145 Australia
| | - Sina Naficy
- School of Chemical Biomolecular Engineering University of Sydney Sydney 2006 Australia
| | - Peter Valtchev
- School of Chemical Biomolecular Engineering University of Sydney Sydney 2006 Australia
| | - Ali Khademhosseini
- Department of Chemical and Biomolecular Engineering Department of Bioengineering Department of Radiology California NanoSystems Institute (CNSI) University of California Los Angeles CA 90095 USA
| | - Fariba Dehghani
- School of Chemical Biomolecular Engineering University of Sydney Sydney 2006 Australia
| |
Collapse
|
33
|
Lam YT, Lecce L, Yuen GSC, Wise SG, Handelsman DJ, Ng MKC. Androgen action augments ischemia-induced, bone marrow progenitor cell-mediated vasculogenesis. Int J Biol Sci 2018; 14:1985-1992. [PMID: 30585262 PMCID: PMC6299365 DOI: 10.7150/ijbs.27378] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2018] [Accepted: 09/05/2018] [Indexed: 02/04/2023] Open
Abstract
Bone marrow-derived progenitor cell-mediated vasculogenesis is a key process for vascular repair and regeneration. However, the role of androgens in the mechanism of ischemia-induced vasculogenesis remains unclear. In this study, a gender-mismatch murine bone marrow transplant model was used to allow tissue tracking of transplanted cells. Bone marrow from 2-month-old male mice was transplanted into irradiated age-matched female recipients. Following the transplantation, ovariectomized female recipients were subjected to unilateral hindlimb ischemia and immediately implanted with either dihydrotestosterone (DHT) or placebo pellets. Laser Doppler perfusion imaging revealed that DHT significantly augmented blood flow recovery, with increased capillary density compared to placebo-treated female recipient controls. Flow cytometry analysis showed that DHT modulated vasculogenesis by increasing Sca1+/CXC4+ progenitor cell production in bone marrow and spleen and enhancing cell mobilization in circulating blood following hindlimb ischemia. Bone marrow cell homing was examined by detecting expression levels of male-specific SRY gene in the ischemic female tissues. DHT treatment promoted bone marrow cell homing to ischemic tissue shown by significantly higher SRY expression compared to placebo-treated females as well as reduced apoptotic features in DHT-treated females, including increased Bcl-2 expression, reduced Bax levels and decreased TUNEL staining. In conclusion, the gender-mismatched bone marrow transplant study shows that androgens directly enhance bone marrow cell-mediated vasculogenesis that contributes to ischemia-induced neovascularization.
Collapse
Affiliation(s)
- Yuen Ting Lam
- The Heart Research Institute, Newtown, Sydney NSW, 2042 Australia.,Sydney Medical School, The University of Sydney, NSW 2006 Australia
| | - Laura Lecce
- The Heart Research Institute, Newtown, Sydney NSW, 2042 Australia.,Sydney Medical School, The University of Sydney, NSW 2006 Australia
| | - Gloria S C Yuen
- The Heart Research Institute, Newtown, Sydney NSW, 2042 Australia.,Sydney Medical School, The University of Sydney, NSW 2006 Australia
| | - Steven G Wise
- The Heart Research Institute, Newtown, Sydney NSW, 2042 Australia.,Sydney Medical School, The University of Sydney, NSW 2006 Australia
| | - David J Handelsman
- ANZAC Research Institute, The University of Sydney, Concord Hospital NSW 2139 Australia
| | - Martin K C Ng
- The Heart Research Institute, Newtown, Sydney NSW, 2042 Australia.,Sydney Medical School, The University of Sydney, NSW 2006 Australia.,Royal Prince Alfred Hospital, Camperdown NSW Australia 2050
| |
Collapse
|
34
|
Stewart CAC, Akhavan B, Hung J, Bao S, Jang JH, Wise SG, Bilek MMM. Multifunctional Protein-Immobilized Plasma Polymer Films for Orthopedic Applications. ACS Biomater Sci Eng 2018; 4:4084-4094. [DOI: 10.1021/acsbiomaterials.8b00954] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
- Callum A. C. Stewart
- School of Physics, University of Sydney, Physics Road, Camperdown, NSW 2006, Australia
- Heart Research Institute, 7 Eliza Street, Newtown, New South Wales 2042, Australia
- Charles Perkins Centre, University of Sydney, Camperdown NSW 2006, Australia
| | - Behnam Akhavan
- School of Physics, University of Sydney, Physics Road, Camperdown, NSW 2006, Australia
- Heart Research Institute, 7 Eliza Street, Newtown, New South Wales 2042, Australia
- School of Aerospace Mechanical and Mechatronic Engineering, University of Sydney, Camperdown, NSW 2006, Australia
| | - Juichien Hung
- Heart Research Institute, 7 Eliza Street, Newtown, New South Wales 2042, Australia
| | - Shisan Bao
- Charles Perkins Centre, University of Sydney, Camperdown NSW 2006, Australia
- Sydney Medical School, University of Sydney, Camperdown, NSW 2006, Australia
| | - Jun-Hyeog Jang
- School of Medicine, Inha University, Incheon 400−712, Korea
| | - Steven G. Wise
- Heart Research Institute, 7 Eliza Street, Newtown, New South Wales 2042, Australia
- Sydney Medical School, University of Sydney, Camperdown, NSW 2006, Australia
| | - Marcela M. M. Bilek
- School of Physics, University of Sydney, Physics Road, Camperdown, NSW 2006, Australia
- Charles Perkins Centre, University of Sydney, Camperdown NSW 2006, Australia
- School of Aerospace Mechanical and Mechatronic Engineering, University of Sydney, Camperdown, NSW 2006, Australia
- Sydney Nano Institute, The University of Sydney, Camperdown, NSW 2006, Australia
| |
Collapse
|
35
|
Kulkarni K, Hung J, Fulcher AJ, Chan AH, Hong A, Forsythe JS, Aguilar MI, Wise SG, Del Borgo MP. β3-Tripeptides Coassemble into Fluorescent Hydrogels for Serial Monitoring in Vivo. ACS Biomater Sci Eng 2018; 4:3843-3847. [DOI: 10.1021/acsbiomaterials.8b01065] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Affiliation(s)
| | - Juichien Hung
- Heart Research Institute, Newtown, New South Wales 2042, Australia
| | | | - Alex H.P. Chan
- Heart Research Institute, Newtown, New South Wales 2042, Australia
| | | | | | | | - Steven G. Wise
- Heart Research Institute, Newtown, New South Wales 2042, Australia
- Sydney Medical School, Sydney University, Sydney, New South Wales 2006, Australia
| | | |
Collapse
|
36
|
Vanags LZ, Tan JT, Galougahi KK, Schaefer A, Wise SG, Murphy A, Ali ZA, Bursill CA. Apolipoprotein A-I Reduces In-Stent Restenosis and Platelet Activation and Alters Neointimal Cellular Phenotype. JACC Basic Transl Sci 2018; 3:200-209. [PMID: 30062205 PMCID: PMC6060078 DOI: 10.1016/j.jacbts.2017.11.006] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/12/2017] [Revised: 10/20/2017] [Accepted: 11/13/2017] [Indexed: 11/04/2022]
Abstract
Even the most advanced drug-eluting stents evoke unresolved issues, including chronic inflammation, late thrombosis, and neoatherosclerosis. This highlights the need for novel strategies that improve stent biocompatibility. Our studies show that apolipoprotein A-I (apoA-I) reduces in-stent restenosis and platelet activation, and enhances endothelialization. These findings have therapeutic implications for improving stent biocompatibility.
Collapse
Key Words
- ABCA1, ATP-binding cassette transporter A1
- CAD, coronary artery disease
- DES, drug-eluting stent(s)
- HDL, high-density lipoprotein
- PBS, phosphate-buffered saline
- PCI, percutaneous coronary intervention
- PPAR, peroxisome proliferator-activated receptor
- SMC, smooth muscle cell
- apoA-I, apolipoprotein A-I
- apoE−/−, apolipoprotein E deficient
- apolipoprotein A-I
- endothelialization
- neointimal hyperplasia
- platelet activation
- rHDL, reconstituted high- density lipoprotein
- stent biocompatibility
Collapse
Affiliation(s)
- Laura Z. Vanags
- Immunobiology Group, The Heart Research Institute, Sydney, Australia
- Sydney Medical School, University of Sydney, Sydney, Australia
| | - Joanne T.M. Tan
- Immunobiology Group, The Heart Research Institute, Sydney, Australia
- Sydney Medical School, University of Sydney, Sydney, Australia
| | - Keyvan K. Galougahi
- Center for Interventional Vascular Therapy, Columbia University, New York, New York
- Cardiovascular Research Foundation, New York, New York
| | - Andreas Schaefer
- Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany
| | - Steven G. Wise
- Immunobiology Group, The Heart Research Institute, Sydney, Australia
- Sydney Medical School, University of Sydney, Sydney, Australia
| | - Andrew Murphy
- Haematopoiesis and Leukocyte Biology Group, Baker IDI Heart and Diabetes Institute, Melbourne, Australia
- Department of Immunology, Monash University, Melbourne, Australia
| | - Ziad A. Ali
- Center for Interventional Vascular Therapy, Columbia University, New York, New York
- Cardiovascular Research Foundation, New York, New York
| | - Christina A. Bursill
- Immunobiology Group, The Heart Research Institute, Sydney, Australia
- Sydney Medical School, University of Sydney, Sydney, Australia
| |
Collapse
|
37
|
Tan RP, Chan AHP, Lennartsson K, Miravet MM, Lee BSL, Rnjak-Kovacina J, Clayton ZE, Cooke JP, Ng MKC, Patel S, Wise SG. Integration of induced pluripotent stem cell-derived endothelial cells with polycaprolactone/gelatin-based electrospun scaffolds for enhanced therapeutic angiogenesis. Stem Cell Res Ther 2018; 9:70. [PMID: 29562916 PMCID: PMC5863387 DOI: 10.1186/s13287-018-0824-2] [Citation(s) in RCA: 40] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2018] [Revised: 02/19/2018] [Accepted: 03/05/2018] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND Induced pluripotent stem-cell derived endothelial cells (iPSC-ECs) can be generated from any somatic cell and their iPSC sources possess unlimited self-renewal. Previous demonstration of their proangiogenic activity makes them a promising cell type for treatment of ischemic injury. As with many other stem cell approaches, the low rate of in-vivo survival has been a major limitation to the efficacy of iPSC-ECs to date. In this study, we aimed to increase the in-vivo lifetime of iPSC-ECs by culturing them on electrospun polycaprolactone (PCL)/gelatin scaffolds, before quantifying the subsequent impact on their proangiogenic function. METHODS iPSC-ECs were isolated and stably transfected with a luciferase reporter to facilitate quantification of cell numbers and non-invasive imaging in-vivo PCL/gelatin scaffolds were engineered using electrospinning to obtain woven meshes of nanofibers. iPSC-ECs were cultured on scaffolds for 7 days. Subsequently, cell growth and function were assessed in vitro followed by implantation in a mouseback subcutaneous model for 7 days. RESULTS Using a matrix of conditions, we found that scaffold blends with ratios of PCL:gelatin of 70:30 (PG73) spun at high flow rates supported the greatest levels of iPSC-EC growth, retention of phenotype, and function in vitro. Implanting iPSC-ECs seeded on PG73 scaffolds in vivo improved their survival up to 3 days, compared to cells directly injected into control wounds, which were no longer observable within 1 h. Enhanced engraftment improved blood perfusion, observed through non-invasive laser Doppler imaging. Immunohistochemistry revealed a corresponding increase in host angiogenic mechanisms characterized by the enhanced recruitment of macrophages and the elevated expression of proangiogenic cytokines vascular endothelial growth factor and placental growth factor. CONCLUSIONS Knowledge of these mechanisms combined with a deeper understanding of the scaffold parameters influencing this function provides the groundwork for optimizing future iPSC-EC therapies utilizing engraftment platforms. The development of combined scaffold and iPSC-EC therapies could ultimately improve therapeutic angiogenesis and the treatment of ischemic injury.
Collapse
Affiliation(s)
- Richard P Tan
- The Heart Research Institute, Sydney, NSW, 2042, Australia. .,Sydney Medical School, University of Sydney, Sydney, NSW, 2006, Australia.
| | - Alex H P Chan
- The Heart Research Institute, Sydney, NSW, 2042, Australia.,Sydney Medical School, University of Sydney, Sydney, NSW, 2006, Australia
| | | | | | - Bob S L Lee
- The Heart Research Institute, Sydney, NSW, 2042, Australia.,Sydney Medical School, University of Sydney, Sydney, NSW, 2006, Australia
| | - Jelena Rnjak-Kovacina
- Graduate School of Biomedical Engineering, University of New South Wales, Sydney, NSW, 2052, Australia
| | - Zoe E Clayton
- The Heart Research Institute, Sydney, NSW, 2042, Australia
| | - John P Cooke
- Department of Cardiovascular Sciences, Houston Methodist Research Institute, Houston, TX, 77030, USA
| | - Martin K C Ng
- The Heart Research Institute, Sydney, NSW, 2042, Australia.,Royal Prince Alfred Hospital, Sydney, NSW, 2042, Australia
| | - Sanjay Patel
- The Heart Research Institute, Sydney, NSW, 2042, Australia.,Royal Prince Alfred Hospital, Sydney, NSW, 2042, Australia
| | - Steven G Wise
- The Heart Research Institute, Sydney, NSW, 2042, Australia.,Sydney Medical School, University of Sydney, Sydney, NSW, 2006, Australia
| |
Collapse
|
38
|
Filipe EC, Santos M, Hung J, Lee BS, Yang N, Chan AH, Ng MK, Rnjak-Kovacina J, Wise SG. Rapid Endothelialization of Off-the-Shelf Small Diameter Silk Vascular Grafts. JACC Basic Transl Sci 2018; 3:38-53. [PMID: 30062193 PMCID: PMC6058932 DOI: 10.1016/j.jacbts.2017.12.003] [Citation(s) in RCA: 38] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/30/2017] [Revised: 12/13/2017] [Accepted: 12/15/2017] [Indexed: 12/12/2022]
Abstract
Synthetic vascular grafts for small diameter revascularization are lacking. Clinically available conduits expanded polytetrafluorethylene and Dacron fail acutely due to thrombosis and in the longer term from neointimal hyperplasia. We report the bioengineering of a cell-free, silk-based vascular graft. In vitro we demonstrate strong, elastic silk conduits that support rapid endothelial cell attachment and spreading while simultaneously resisting blood clot and fibrin network formation. In vivo rat studies show complete graft patency at all time points, rapid endothelialization, and stabilization and contraction of neointimal hyperplasia. These studies show the potential of silk as an off-the-shelf small diameter vascular graft.
Collapse
Affiliation(s)
- Elysse C. Filipe
- Applied Materials Group, The Heart Research Institute, Sydney, New South Wales, Australia
- Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | - Miguel Santos
- Applied Materials Group, The Heart Research Institute, Sydney, New South Wales, Australia
- Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | - Juichien Hung
- Applied Materials Group, The Heart Research Institute, Sydney, New South Wales, Australia
| | - Bob S.L. Lee
- Applied Materials Group, The Heart Research Institute, Sydney, New South Wales, Australia
- Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | - Nianji Yang
- Applied Materials Group, The Heart Research Institute, Sydney, New South Wales, Australia
- Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | - Alex H.P. Chan
- Applied Materials Group, The Heart Research Institute, Sydney, New South Wales, Australia
- Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | - Martin K.C. Ng
- Applied Materials Group, The Heart Research Institute, Sydney, New South Wales, Australia
- Department of Cardiology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
| | - Jelena Rnjak-Kovacina
- Graduate School of Biomedical Engineering, University of New South Wales–Sydney, Sydney, New South Wales, Australia
| | - Steven G. Wise
- Applied Materials Group, The Heart Research Institute, Sydney, New South Wales, Australia
- Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| |
Collapse
|
39
|
Degendorfer G, Chuang CY, Mariotti M, Hammer A, Hoefler G, Hägglund P, Malle E, Wise SG, Davies MJ. Exposure of tropoelastin to peroxynitrous acid gives high yields of nitrated tyrosine residues, di-tyrosine cross-links and altered protein structure and function. Free Radic Biol Med 2018; 115:219-231. [PMID: 29191462 DOI: 10.1016/j.freeradbiomed.2017.11.019] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/14/2017] [Revised: 11/06/2017] [Accepted: 11/24/2017] [Indexed: 12/18/2022]
Abstract
Elastin is an abundant extracellular matrix protein in elastic tissues, including the lungs, skin and arteries, and comprises 30-57% of the aorta by dry mass. The monomeric precursor, tropoelastin (TE), undergoes complex processing during elastogenesis to form mature elastic fibres. Peroxynitrous acid (ONOOH), a potent oxidising and nitrating agent, is formed in vivo from superoxide and nitric oxide radicals. Considerable evidence supports ONOOH formation in the inflamed artery wall, and a role for this species in the development of human atherosclerotic lesions, with ONOOH-damaged extracellular matrix implicated in lesion rupture. We demonstrate that TE is highly sensitive to ONOOH, with this resulting in extensive dimerization, fragmentation and nitration of Tyr residues to give 3-nitrotyrosine (3-nitroTyr). This occurs with equimolar or greater levels of oxidant and increases in a dose-dependent manner. Quantification of Tyr loss and 3-nitroTyr formation indicates extensive Tyr modification with up to two modified Tyr per protein molecule, and up to 8% conversion of initial ONOOH to 3-nitroTyr. These effects were modulated by bicarbonate, an alternative target for ONOOH. Inter- and intra-protein di-tyrosine cross-links have been characterized by mass spectrometry. Examination of human atherosclerotic lesions shows colocalization of 3-nitroTyr with elastin epitopes, consistent with TE or elastin modification in vivo, and also an association of 3-nitroTyr containing proteins and elastin with lipid deposits. These data suggest that exposure of TE to ONOOH gives marked chemical and structural changes to TE and altered matrix assembly, and that such damage accumulates in human arterial tissue during the development of atherosclerosis.
Collapse
Affiliation(s)
| | - Christine Y Chuang
- Dept. of Biomedical Sciences, Panum Institute, University of Copenhagen, Copenhagen, Denmark
| | - Michele Mariotti
- Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark
| | - Astrid Hammer
- Institute of Cell Biology, Histology and Embryology, Medical University of Graz, Graz, Austria
| | - Gerald Hoefler
- Institute of Pathology, Medical University of Graz, Graz, Austria
| | - Per Hägglund
- Dept. of Biomedical Sciences, Panum Institute, University of Copenhagen, Copenhagen, Denmark; Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark
| | - Ernst Malle
- Institute of Molecular Biology and Biochemistry, Medical University of Graz, Graz, Austria
| | - Steven G Wise
- The Heart Research Institute, Sydney, Australia; Faculty of Medicine, University of Sydney, Sydney, Australia
| | - Michael J Davies
- The Heart Research Institute, Sydney, Australia; Dept. of Biomedical Sciences, Panum Institute, University of Copenhagen, Copenhagen, Denmark; Faculty of Medicine, University of Sydney, Sydney, Australia.
| |
Collapse
|
40
|
Abstract
Tropoelastin, as the monomer unit of elastin, assembles into elastic fibers that impart strength and resilience to elastic tissues. Tropoelastin is also widely used to manufacture versatile materials with specific mechanical and biological properties. The assembly of tropoelastin into elastic fibers or biomaterials is crucially influenced by key submolecular regions and specific residues within these domains. In this work, we identify the functional contributions of two rarely occurring negatively charged residues, glutamate 345 in domain 19 and glutamate 414 in domain 21, in jointly maintaining the native conformation of the tropoelastin hinge, bridge and foot regions. Alanine substitution of E345 and/or E414 variably alters the positioning and interactive accessibility of these regions, as illustrated by nanostructural studies and detected by antibody and cell probes. These structural changes are associated with a lower propensity for monomer coacervation, cross-linking into morphologically and functionally atypical hydrogels, and markedly impaired and abnormal elastic fiber formation. Our work indicates the crucial significance of both E345 and E414 residues in modulating specific local structure and higher-order assembly of human tropoelastin.
Collapse
Affiliation(s)
- Giselle
C. Yeo
- Charles Perkins Centre, School of Life and
Environmental Sciences, School of Physics, Sydney Medical School, and Bosch Institute, The University of Sydney, Sydney, New South Wales 2006, Australia
| | - Clair Baldock
- Wellcome
Trust Centre for Cell-Matrix Research, Faculty of Biology, Medicine
and Health, University of Manchester, Manchester M13 9PT, United Kingdom
| | - Steven G. Wise
- Charles Perkins Centre, School of Life and
Environmental Sciences, School of Physics, Sydney Medical School, and Bosch Institute, The University of Sydney, Sydney, New South Wales 2006, Australia
- The
Heart Research Institute, 7 Eliza Street, Newtown, New South Wales 2050, Australia
| | - Anthony S. Weiss
- Charles Perkins Centre, School of Life and
Environmental Sciences, School of Physics, Sydney Medical School, and Bosch Institute, The University of Sydney, Sydney, New South Wales 2006, Australia
| |
Collapse
|
41
|
Kondyurina I, Wise SG, Ngo AKY, Filipe EC, Kondyurin A, Weiss AS, Bao S, Bilek MMM. Plasma mediated protein immobilisation enhances the vascular compatibility of polyurethane with tissue matched mechanical properties. Biomed Mater 2017; 12:045002. [DOI: 10.1088/1748-605x/aa6eb6] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
|
42
|
Vanags LZ, Tan JTM, Santos M, Michael PS, Ali Z, Bilek MMM, Wise SG, Bursill CA. Plasma activated coating immobilizes apolipoprotein A-I to stainless steel surfaces in its bioactive form and enhances biocompatibility. Nanomedicine 2017; 13:2141-2150. [PMID: 28668625 DOI: 10.1016/j.nano.2017.06.012] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/16/2016] [Revised: 05/24/2017] [Accepted: 06/21/2017] [Indexed: 11/29/2022]
Abstract
We utilized a plasma activated coating (PAC) to covalently bind the active component of high density lipoproteins (HDL), apolipoprotein (apo) A-I, to stainless steel (SS) surfaces. ApoA-I suppresses restenosis and thrombosis and may therefore improve SS stent biocompatibility. PAC-coated SS significantly increased the covalent attachment of apoA-I, compared to SS alone. In static and dynamic flow thrombosis assays, PAC+apoA-I inhibited thrombosis and reduced platelet activation marker p-selectin. PAC+apoA-I reduced smooth muscle cell attachment and proliferation, and augmented EC attachment to PAC. We then coated PAC onto murine SS stents and found it did not peel or delaminate following crimping/expansion. ApoA-I was immobilized onto PAC-SS stents and was retained as a monolayer when exposed to pulsatile flow in vivo in a murine stent model. In conclusion, ApoA-I immobilized on PAC withstands pulsatile flow in vivo and retains its bioactivity, exhibiting anti-thrombotic and anti-restenotic properties, demonstrating the potential to improve stent biocompatibility.
Collapse
Affiliation(s)
- Laura Z Vanags
- The Heart Research Institute, Sydney, New South Wales, Australia; Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
| | - Joanne T M Tan
- The Heart Research Institute, Sydney, New South Wales, Australia; Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
| | - Miguel Santos
- The Heart Research Institute, Sydney, New South Wales, Australia; Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia; School of Physics, University of Sydney, Sydney, New South Wales, Australia.
| | - Praveesuda S Michael
- The Heart Research Institute, Sydney, New South Wales, Australia; Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
| | - Ziad Ali
- Translational Medicine, University of Columbia, NY, New York, USA.
| | - Marcela M M Bilek
- School of Physics, University of Sydney, Sydney, New South Wales, Australia.
| | - Steven G Wise
- The Heart Research Institute, Sydney, New South Wales, Australia; Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia; School of Molecular Bioscience, University of Sydney, Sydney, New South Wales, Australia.
| | - Christina A Bursill
- The Heart Research Institute, Sydney, New South Wales, Australia; Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
| |
Collapse
|
43
|
Tan RP, Lee BS, Chan AH, Yuen SCG, Hung J, Wise SG, Ng MK. Non-invasive tracking of injected bone marrow mononuclear cells to injury and implanted biomaterials. Acta Biomater 2017; 53:378-388. [PMID: 28167301 DOI: 10.1016/j.actbio.2017.02.002] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2016] [Revised: 01/31/2017] [Accepted: 02/01/2017] [Indexed: 02/07/2023]
Abstract
Biomaterial scaffolds enhancing the engraftment of transplanted bone-marrow mononuclear cells (BM-MNC) have enormous potential for tissue regeneration applications. However, development of appropriate materials is challenging given the precise microenvironments required to support BM-MNC engraftment and function. In this study, we have developed a non-invasive, real-time tracking model of injected BM-MNC engraftment to wounds and implanted biomaterial scaffolds. BM-MNCs, encoded with firefly luciferase and enhanced GFP reporter genes, were tail vein injected into subcutaneously wounded mice. Luciferase-dependent cell bioluminescence curves revealed our injected BM-MNCs homed to and engrafted within subcutaneous wound sites over the course of 21days. Further immunohistochemical characterization showed that these engrafted cells drove functional changes by increasing the number of immune cells present at early time points and remodelling cell phenotypes at later time points. Using this model, we subcutaneously implanted electrospun polycaprolactone (PCL) and PCL/Collagen scaffolds, to determine differences in exogenous BM-MNC response to these materials. Following BM-MNC injection, immunohistochemical analysis revealed a high exogenous BM-MNC density around the periphery of PCL scaffolds consistent with a classical foreign body response. In contrast, transplanted BM-MNCs engrafted throughout PCL/Collagen scaffolds indicating an improved biological response. Importantly, these differences were closely correlated with the real-time bioluminescence curves, with PCL/Collagen scaffolds exhibiting a∼2-fold increase in maximum bioluminescence compared with PCL scaffolds. Collectively, these results demonstrate a new longitudinal cell tracking model that can non-invasively determine transplanted BM-MNC homing and engraftment to biomaterials, providing a valuable tool to inform the design scaffolds that help augment current BM-MNC tissue engineering strategies. STATEMENT OF SIGNIFICANCE Tracking the dynamic behaviour of transplanted bone-marrow mononuclear cells (BM-MNCs) is a long-standing research goal. Conventional methods involving contrast and tracer agents interfere with cellular function while also yielding false signals. The use of bioluminescence addresses these shortcomings while allowing for real-time non-invasive tracking in vivo. Given the failures of transplanted BM-MNCs to engraft into injured tissue, biomaterial scaffolds capable of attracting and enhancing BM-MNC engraftment at sites of injury are highly sought in numerous tissue engineering applications. To this end, the results from this study demonstrate a new longitudinal tracking model that can non-invasively determine exogenous BM-MNC homing and engraftment to biomaterials, providing a valuable tool to inform the design of scaffolds with implications for countless tissue engineering applications.
Collapse
|
44
|
Chan AHP, Tan RP, Michael PL, Lee BSL, Vanags LZ, Ng MKC, Bursill CA, Wise SG. Evaluation of synthetic vascular grafts in a mouse carotid grafting model. PLoS One 2017; 12:e0174773. [PMID: 28355300 PMCID: PMC5371373 DOI: 10.1371/journal.pone.0174773] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2016] [Accepted: 03/15/2017] [Indexed: 11/24/2022] Open
Abstract
Current animal models for the evaluation of synthetic grafts are lacking many of the molecular tools and transgenic studies available to other branches of biology. A mouse model of vascular grafting would allow for the study of molecular mechanisms of graft failure, including in the context of clinically relevant disease states. In this study, we comprehensively characterise a sutureless grafting model which facilitates the evaluation of synthetic grafts in the mouse carotid artery. Using conduits electrospun from polycaprolactone (PCL) we show the gradual development of a significant neointima within 28 days, found to be greatest at the anastomoses. Histological analysis showed temporal increases in smooth muscle cell and collagen content within the neointima, demonstrating its maturation. Endothelialisation of the PCL grafts, assessed by scanning electron microscopy (SEM) analysis and CD31 staining, was near complete within 28 days, together replicating two critical aspects of graft performance. To further demonstrate the potential of this mouse model, we used longitudinal non-invasive tracking of bone-marrow mononuclear cells from a transgenic mouse strain with a dual reporter construct encoding both luciferase and green fluorescent protein (GFP). This enabled characterisation of mononuclear cell homing and engraftment to PCL using bioluminescence imaging and histological staining over time (7, 14 and 28 days). We observed peak luminescence at 7 days post-graft implantation that persisted until sacrifice at 28 days. Collectively, we have established and characterised a high-throughput model of grafting that allows for the evaluation of key clinical drivers of graft performance.
Collapse
Affiliation(s)
- Alex H. P. Chan
- The Heart Research Institute, Sydney, New South Wales, Australia
- Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | - Richard P. Tan
- The Heart Research Institute, Sydney, New South Wales, Australia
- Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | - Praveesuda L. Michael
- The Heart Research Institute, Sydney, New South Wales, Australia
- Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | - Bob S. L. Lee
- The Heart Research Institute, Sydney, New South Wales, Australia
| | - Laura Z. Vanags
- The Heart Research Institute, Sydney, New South Wales, Australia
- Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | - Martin K. C. Ng
- The Heart Research Institute, Sydney, New South Wales, Australia
- Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
- Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
| | - Christina A. Bursill
- The Heart Research Institute, Sydney, New South Wales, Australia
- Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | - Steven G. Wise
- The Heart Research Institute, Sydney, New South Wales, Australia
- Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
- School of Life and Environmental Sciences, University of Sydney, Sydney, New South Wales, Australia
- * E-mail:
| |
Collapse
|
45
|
Wise SG, Liu H, Yeo GC, Michael PL, Chan AHP, Ngo AKY, Bilek MMM, Bao S, Weiss AS. Blended Polyurethane and Tropoelastin as a Novel Class of Biologically Interactive Elastomer. Tissue Eng Part A 2016; 22:524-33. [PMID: 26857114 DOI: 10.1089/ten.tea.2015.0409] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Abstract
Polyurethanes are versatile elastomers but suffer from biological limitations such as poor control over cell attachment and the associated disadvantages of increased fibrosis. We address this problem by presenting a novel strategy that retains elasticity while modulating biological performance. We describe a new biomaterial that comprises a blend of synthetic and natural elastomers: the biostable polyurethane Elast-Eon and the recombinant human tropoelastin protein. We demonstrate that the hybrid constructs yield a class of coblended elastomers with unique physical properties. Hybrid constructs displayed higher elasticity and linear stress-strain responses over more than threefold strain. The hybrid materials showed increased overall porosity and swelling in comparison to polyurethane alone, facilitating enhanced cellular interactions. In vitro, human dermal fibroblasts showed enhanced proliferation, while in vivo, following subcutaneous implantation in mice, hybrid scaffolds displayed a reduced fibrotic response and tunable degradation rate. To our knowledge, this is the first example of a blend of synthetic and natural elastomers and is a promising approach for generating tailored bioactive scaffolds for tissue repair.
Collapse
Affiliation(s)
- Steven G Wise
- 1 The Heart Research Institute , Sydney, Australia .,2 Sydney Medical School, University of Sydney , Sydney, Australia .,3 School of Molecular Bioscience, University of Sydney , Sydney, Australia
| | - Hongjuan Liu
- 2 Sydney Medical School, University of Sydney , Sydney, Australia .,4 Discipline of Pathology and School of Medical Science, University of Sydney , Sydney, Australia .,5 Charles Perkins Centre, University of Sydney , Sydney, Australia .,6 Bosch Institute, University of Sydney , Sydney, Australia
| | - Giselle C Yeo
- 3 School of Molecular Bioscience, University of Sydney , Sydney, Australia .,5 Charles Perkins Centre, University of Sydney , Sydney, Australia
| | - Praveesuda L Michael
- 1 The Heart Research Institute , Sydney, Australia .,2 Sydney Medical School, University of Sydney , Sydney, Australia
| | - Alex H P Chan
- 1 The Heart Research Institute , Sydney, Australia .,2 Sydney Medical School, University of Sydney , Sydney, Australia
| | - Alan K Y Ngo
- 3 School of Molecular Bioscience, University of Sydney , Sydney, Australia
| | | | - Shisan Bao
- 2 Sydney Medical School, University of Sydney , Sydney, Australia .,4 Discipline of Pathology and School of Medical Science, University of Sydney , Sydney, Australia .,5 Charles Perkins Centre, University of Sydney , Sydney, Australia .,6 Bosch Institute, University of Sydney , Sydney, Australia
| | - Anthony S Weiss
- 3 School of Molecular Bioscience, University of Sydney , Sydney, Australia .,5 Charles Perkins Centre, University of Sydney , Sydney, Australia .,6 Bosch Institute, University of Sydney , Sydney, Australia
| |
Collapse
|
46
|
Abstract
Although plasma polymerization is traditionally considered as a substrate-independent process, we present evidence that the propensity of a substrate to form carbide bonds regulates the growth mechanisms of plasma polymer (PP) films. The manner by which the first layers of PP films grow determines the adhesion and robustness of the film. Zirconium, titanium, and silicon substrates were used to study the early stages of PP film formation from a mixture of acetylene, nitrogen, and argon precursor gases. The correlation of initial growth mechanisms with the robustness of the films was evaluated through incubation of coated substrates in simulated body fluid (SBF) at 37° for 2 months. It was demonstrated that the excellent zirconium/titanium-PP film adhesion is linked to the formation of metallic carbide and oxycarbide bonds during the initial stages of film formation, where a 2D-like, layer-by-layer (Frank-van der Merwe) manner of growth was observed. On the contrary, the lower propensity of the silicon surface to form carbides leads to a 3D, island-like (Volmer-Weber) growth mode that creates a sponge-like interphase near the substrate, resulting in inferior adhesion and poor film stability in SBF. Our findings shed light on the growth mechanisms of the first layers of PP films and challenge the property of substrate independence typically attributed to plasma polymerized coatings.
Collapse
Affiliation(s)
- Behnam Akhavan
- School of Physics, University of Sydney , Sydney, New South Wales 2006, Australia
| | - Steven G Wise
- The Heart Research Institute , Sydney, New South Wales 2042, Australia
- Sydney Medical School, University of Sydney , Sydney, New South Wales 2006, Australia
| | - Marcela M M Bilek
- School of Physics, University of Sydney , Sydney, New South Wales 2006, Australia
| |
Collapse
|
47
|
Wise SG, Liu H, Kondyurin A, Byrom MJ, Bannon PG, Edwards GA, Weiss AS, Bao S, Bilek MM. Plasma Ion Activated Expanded Polytetrafluoroethylene Vascular Grafts with a Covalently Immobilized Recombinant Human Tropoelastin Coating Reducing Neointimal Hyperplasia. ACS Biomater Sci Eng 2016; 2:1286-1297. [DOI: 10.1021/acsbiomaterials.6b00208] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Steven G. Wise
- The Heart Research Institute, 7 Eliza Street, Newtown, Sydney, New South Wales 2042, Australia
- Sydney
Medical School, University of Sydney, Edward Ford Building (A27), Fisher
Road, Sydney, New South Wales 2006, Australia
- School
of Molecular Bioscience, University of Sydney, Biochemistry Building (G08), Butlin
Avenue, Sydney, New South
Wales 2006, Australia
| | - Hongjuan Liu
- Department
of Pathology, University of Sydney, Blackburn Building (D06), Blackburn Circuit, Sydney, New South Wales 2006, Australia
| | - Alexey Kondyurin
- School
of Physics (A28), University of Sydney, Physics Road, Sydney, New South Wales 2006, Australia
| | - Michael J. Byrom
- The Heart Research Institute, 7 Eliza Street, Newtown, Sydney, New South Wales 2042, Australia
- The Baird Institute, Suite 305, 100 Carillon Avenue, Newtown, Sydney, New South Wales 2042, Australia
| | - Paul G. Bannon
- Sydney
Medical School, University of Sydney, Edward Ford Building (A27), Fisher
Road, Sydney, New South Wales 2006, Australia
- The Baird Institute, Suite 305, 100 Carillon Avenue, Newtown, Sydney, New South Wales 2042, Australia
| | - Glenn A. Edwards
- School
of Veterinary Science, University of Melbourne, 757 Swanston Street, Parkville, Victoria 3030, Australia
| | - Anthony S. Weiss
- School
of Molecular Bioscience, University of Sydney, Biochemistry Building (G08), Butlin
Avenue, Sydney, New South
Wales 2006, Australia
- Bosch
Institute, University of Sydney, Anderson Stuart Building (F13), Fisher Road, Sydney, New
South Wales 2006, Australia
- Charles
Perkins Centre (D17), University of Sydney, John Hopkins Drive, Sydney, New South Wales 2006, Australia
| | - Shisan Bao
- Department
of Pathology, University of Sydney, Blackburn Building (D06), Blackburn Circuit, Sydney, New South Wales 2006, Australia
| | - Marcela M. Bilek
- School
of Physics (A28), University of Sydney, Physics Road, Sydney, New South Wales 2006, Australia
| |
Collapse
|
48
|
Abstract
AIMS This study aimed to characterize the role of tropoelastin in eliciting a nitric oxide response in endothelial cells. MATERIALS AND METHODS Nitric oxide production in cells was quantified following the addition of known nitric oxide synthase pathway inhibitors such as LNAME and 1400W. The effect of eNOS siRNA knockdowns was studied using western blotting and assessed in the presence of PI3K-inhibitor, wortmannin. RESULTS Tropoelastin-induced nitric oxide production was LNAME and wortmannin sensitive, while being unaffected by treatment with 1400W. CONCLUSION Tropoelastin acts through a PI3K-specific pathway that leads to the phosphorylation of eNOS to enhance nitric oxide production in endothelial cells. This result points to the benefit of the use of tropoelastin in vascular applications, where NO production is a characteristic marker of vascular health.
Collapse
Affiliation(s)
- Matti A Hiob
- School of Life & Environmental Biosciences, University of Sydney, Sydney, NSW 2006, Australia.,Charles Perkins Centre, University of Sydney, Sydney, NSW 2006, Australia
| | - Andy E Trane
- Centre for Heart Lung Innovation, St Paul's Hospital, Vancouver, BC, V6Z1Y6, Canada.,Department of Anesthesiology, Pharmacology & Therapeutics, University of British Columbia, Vancouver, Canada
| | - Steven G Wise
- School of Life & Environmental Biosciences, University of Sydney, Sydney, NSW 2006, Australia.,Sydney Medical School, University of Sydney, NSW 2006, Australia.,The Heart Research Institute, Sydney, NSW, 2042, Australia
| | - Pascal N Bernatchez
- Centre for Heart Lung Innovation, St Paul's Hospital, Vancouver, BC, V6Z1Y6, Canada.,Department of Anesthesiology, Pharmacology & Therapeutics, University of British Columbia, Vancouver, Canada
| | - Anthony S Weiss
- School of Life & Environmental Biosciences, University of Sydney, Sydney, NSW 2006, Australia.,Charles Perkins Centre, University of Sydney, Sydney, NSW 2006, Australia.,Bosch Institute, University of Sydney, Sydney, NSW 2006, Australia
| |
Collapse
|
49
|
Santos M, Filipe EC, Michael PL, Hung J, Wise SG, Bilek MMM. Mechanically Robust Plasma-Activated Interfaces Optimized for Vascular Stent Applications. ACS Appl Mater Interfaces 2016; 8:9635-9650. [PMID: 27015083 DOI: 10.1021/acsami.6b01279] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
The long-term performance of many medical implants is limited by the use of inherently incompatible and bioinert materials. Metallic alloys, ceramics, and polymers commonly used in cardiovascular devices encourage clot formation and fail to promote the appropriate molecular signaling required for complete implant integration. Surface coating strategies have been proposed for these materials, but coronary stents are particularly problematic as the large surface deformations they experience in deployment require a mechanically robust coating interface. Here, we demonstrate a single-step ion-assisted plasma deposition process to tailor plasma-activated interfaces to meet current clinical demands for vascular implants. Using a process control-feedback strategy which predicts crucial coating growth mechanisms by adopting a suitable macroscopic plasma description in combination with noninvasive plasma diagnostics, we describe the optimal conditions to generate highly reproducible, industry-scalable stent coatings. These interfaces are mechanically robust, resisting delamination even upon plastic deformation of the underlying material, and were developed in consideration of the need for hemocompatibility and the capacity for biomolecule immobilization. Our optimized coating conditions combine the best mechanical properties with strong covalent attachment capacity and excellent blood compatibility in initial testing with plasma and whole blood, demonstrating the potential for improved vascular stent coatings.
Collapse
Affiliation(s)
- Miguel Santos
- Applied Materials Group, The Heart Research Institute , 7 Eliza Street, Newtown, New South Wales 2042, Australia
| | - Elysse C Filipe
- Applied Materials Group, The Heart Research Institute , 7 Eliza Street, Newtown, New South Wales 2042, Australia
| | - Praveesuda L Michael
- Applied Materials Group, The Heart Research Institute , 7 Eliza Street, Newtown, New South Wales 2042, Australia
| | - Juichien Hung
- Applied Materials Group, The Heart Research Institute , 7 Eliza Street, Newtown, New South Wales 2042, Australia
| | - Steven G Wise
- Applied Materials Group, The Heart Research Institute , 7 Eliza Street, Newtown, New South Wales 2042, Australia
| | | |
Collapse
|
50
|
Yeo GC, Tarakanova A, Baldock C, Wise SG, Buehler MJ, Weiss AS. Subtle balance of tropoelastin molecular shape and flexibility regulates dynamics and hierarchical assembly. Sci Adv 2016; 2:e1501145. [PMID: 26998516 PMCID: PMC4795673 DOI: 10.1126/sciadv.1501145] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/23/2015] [Accepted: 11/20/2015] [Indexed: 05/02/2023]
Abstract
The assembly of the tropoelastin monomer into elastin is vital for conferring elasticity on blood vessels, skin, and lungs. Tropoelastin has dual needs for flexibility and structure in self-assembly. We explore the structure-dynamics-function interplay, consider the duality of molecular order and disorder, and identify equally significant functional contributions by local and global structures. To study these organizational stratifications, we perturb a key hinge region by expressing an exon that is universally spliced out in human tropoelastins. We find a herniated nanostructure with a displaced C terminus and explain by molecular modeling that flexible helices are replaced with substantial β sheets. We see atypical higher-order cross-linking and inefficient assembly into discontinuous, thick elastic fibers. We explain this dysfunction by correlating local and global structural effects with changes in the molecule's assembly dynamics. This work has general implications for our understanding of elastomeric proteins, which balance disordered regions with defined structural modules at multiple scales for functional assembly.
Collapse
Affiliation(s)
- Giselle C. Yeo
- Charles Perkins Centre, The University of Sydney, Camperdown, New South Wales 2006, Australia
- School of Molecular Bioscience, The University of Sydney, Sydney, New South Wales 2006, Australia
| | - Anna Tarakanova
- Laboratory for Atomistic and Molecular Mechanics, Department of Civil and Environmental Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA
| | - Clair Baldock
- Wellcome Trust Centre for Cell-Matrix Research, Faculty of Life Sciences, University of Manchester, Manchester M13 9PT, UK
| | - Steven G. Wise
- The Heart Research Institute, Newtown, New South Wales 2050, Australia
| | - Markus J. Buehler
- Laboratory for Atomistic and Molecular Mechanics, Department of Civil and Environmental Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA
| | - Anthony S. Weiss
- Charles Perkins Centre, The University of Sydney, Camperdown, New South Wales 2006, Australia
- School of Molecular Bioscience, The University of Sydney, Sydney, New South Wales 2006, Australia
- Bosch Institute, The University of Sydney, Sydney, New South Wales 2006, Australia
| |
Collapse
|